Page last updated: 2024-12-08

aminopterin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Aminopterin: A folic acid derivative used as a rodenticide that has been shown to be teratogenic. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID169371
CHEMBL ID376180
CHEBI ID22526
SCHEMBL ID1626034
SCHEMBL ID23086141
MeSH IDM0000962

Synonyms (96)

Synonym
BIDD:GT0600
n-(4-(((2,4-diamino-6-pteridinyl)methyl)amino)benzoyl)-l-glutamic acid
CHEBI:22526 ,
n-(4-{[(2,4-diaminopteridin-6-yl)methyl]amino}benzoyl)-l-glutamic acid
aminopterin, powder
nsc 739
hsdb 6374
a-ninopterin
glutamic acid, n-(p-(((2,4-diamino-6-pteridinyl)methyl)amino)benzoyl)-, l-
4'-amino-folsaeure
pteramina [czech]
ccris 5856
n-(4-(((2,4-diamino-6-pteridyl)-methyl)amino)benzoyl)-l-glutamic acid
aminopterinum
l-glutamic acid, n-(4-(((2,4-diamino-6-pteridinyl)methyl)amino)benzoyl)-
4-amino-4-desoxy-pteroylglutaminsaeure
4-amino pteroylglutamic acid
kyselina n-(p-((2,4-diamino-6-pteridinyl)methyl)benzoyl)-l(+)-glutamova [czech]
n-(1-((2,4-diamino-6-pteridinylmethyl)amino)benzoyl)glutaminsaeure
4'-desoxy-4'-aminofolsaeure
ai3-26079
einecs 200-209-9
kyselina 4-aminopteroylglutamova [czech]
brn 0069045
aminopteridine
kyselina 4-aminolistova [czech]
kyselina n-(p-((2,4-diamino-6-pteridinylmethyl)amino)benzoyl)-l(+)-glutamova [czech]
l-glutamic acid, n-[4-[[(2,4-diamino-6-pteridinyl)methyl]amino]benzoyl]-
nsc257456
(2s)-2-[[4-[(2,4-diaminopteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
4-aminofolic acid
4-amino-pga
4-aminopteroylglutamic acid
ent-26079
nsc-739
aminopterin
nsc739
apga
54-62-6
aminopterine
4-amino-4-deoxypteroylglutamate
folic acid, 4-amino-
aminopterin, powder, bioreagent, suitable for cell culture
aminopterin, hybri-max(tm), 50 x, gamma-irradiated, lyophilized powder, bioxtra, suitable for hybridoma
A-7170 ,
aminotrexate
CHEMBL376180
4-aminopteroic acid
aminopteroylglutamic acid
NCGC00015038-03
NCGC00254512-01
tox21_300627
(2s)-2-[[4-[[2,4-bis(azanyl)pteridin-6-yl]methylamino]phenyl]carbonylamino]pentanedioic acid
(2s)-2-[[[4-[(2,4-diamino-6-pteridinyl)methylamino]phenyl]-oxomethyl]amino]pentanedioic acid
A830273
4-aminopteroyl-l-glutamic acid
A0410
dtxsid3022588 ,
tox21_110069
cas-54-62-6
dtxcid802588
bdbm50367055
kyselina 4-aminopteroylglutamova
4-26-00-03831 (beilstein handbook reference)
jyb41ctm2q ,
kyselina n-(p-((2,4-diamino-6-pteridinylmethyl)amino)benzoyl)-l(+)-glutamova
unii-jyb41ctm2q
kyselina 4-aminolistova
kyselina n-(p-((2,4-diamino-6-pteridinyl)methyl)benzoyl)-l(+)-glutamova
4KN1
minopterin
DB08878
SCHEMBL1626034
04j ,
methotrexate impurity b [ep impurity]
aminopterin [mi]
n-(p-(((2,4-diamino-6-pteridinyl)methyl)amino)benzoyl)glutamic acid
aminopterin [who-dd]
aminopterin [hsdb]
TVZGACDUOSZQKY-LBPRGKRZSA-N
mfcd00036692
methotrexate rc b ( aminopterin)
(2s)-2-[[4-[[(2,4-diaminopteridin-6-yl)methyl]amino]benzoyl]amino]pentanedioic acid (4-aminofolic acid, aminopterin)
(s)-2-(4-((2,4-diaminopteridin-6-yl)methylamino)benzamido)pentanedioic acid
HY-14518
CS-0003421
Q415734
2-(4-(((2,4-diaminopteridin-6-yl)methyl)amino)benzamido)pentanedioic acid
54-62-6 (free acid)
(4-(((2,4-diaminopteridin-6-yl)methyl)amino)benzoyl)-l-glutamic acid
NCGC00348366-01
SCHEMBL23086141
(s)-2-(4-(((2,4-diaminopteridin-6-yl)methyl)amino)benzamido)pentanedioic acid
AKOS040759239
(2s)-2-[(4-{[(2,4-diaminopteridin-6-yl)methyl]amino}phenyl)formamido]pentanedioic acid
EN300-7480753

Research Excerpts

Overview

Aminopterin (AMT) is a potent folate analog that is no longer in routine clinical use.

ExcerptReferenceRelevance
""Aminopterin" is a toxic drug, and its administration must be carefully supervised."( Effect of "aminopterin" on epithelial tissues.
Gubner, R, 1983
)
1.28
"Aminopterin (AMT) is a potent folate analog that is no longer in routine clinical use. "( Phase I and pharmacokinetic trial of aminopterin in patients with refractory malignancies.
Hum, M; Kamen, BA; Marling-Cason, M; Ratliff, AF; Rose, K; Wilson, J; Winick, N, 1998
)
2.02

Effects

Aminopterin (AMT) has been suggested to provide clinical advantages over MTX and other antifolates. Aminopterin has a more drastic cytotoxic effect than cyromazine.

ExcerptReferenceRelevance
"Aminopterin has a more drastic cytotoxic effect than cyromazine and it also interferes with the formation of epicuticle."( Ultrastructural changes in the cuticle of the sheep blowfly, Lucilia, induced by certain insecticides and biological inhibitors.
Binnington, KC, 1985
)
0.99
"Aminopterin (AMT) has been suggested to provide clinical advantages over MTX and other antifolates."( Methotrexate and aminopterin exhibit similar in vitro and in vivo preclinical activity against acute lymphoblastic leukaemia and lymphoma.
Hall, CP; Harutyunyan, N; Kang, MH; Lock, RB; Papa, RA, 2009
)
1.41
"Aminopterin has a more drastic cytotoxic effect than cyromazine and it also interferes with the formation of epicuticle."( Ultrastructural changes in the cuticle of the sheep blowfly, Lucilia, induced by certain insecticides and biological inhibitors.
Binnington, KC, 1985
)
0.99

Treatment

ExcerptReferenceRelevance
"Upon treatment with aminopterin, the cells readily underwent an apoptotic process, as assessed by DNA fragmentation assay and electron microscopic analysis."( Requirement of de novo protein synthesis for aminopterin-induced apoptosis in a mouse myeloma cell line.
Cho, YJ; Choi, Y; Chung, YH; Paik, DJ; Youn, J, 2001
)
0.89

Toxicity

ExcerptReferenceRelevance
"10-DAM appears to be as beneficial and as safe as MTX for the treatment of RA."( Efficacy and safety of 10-deazaaminopterin in the treatment of rheumatoid arthritis. A one-year continuation, double-blind study.
Alarcón, GS; Castañeda, O; Ferrándiz, M; Koopman, WJ; Krumdieck, CL, 1992
)
0.57
" 3'-Fluoroaminopterin was, however, twice as toxic as aminopterin to both cell lines."( Novel fluorinated antifolates. Enzyme inhibition and cytotoxicity studies on 2'- and 3'-fluoroaminopterin.
Henkin, J; Washtien, WL, 1983
)
0.89
"10-EDAM may provide an alternative antifolate therapy in the clinical management of inflammatory arthritis, and appears to be less toxic than MTX."( Comparative efficacy and toxicity of 10-ethyl-10-deazaaminopterin and methotrexate in a mycobacterial rat arthritis model.
Ramos-Remus, C; Russell, AS; Skeith, KJ, 1994
)
0.54
" Adverse events across treatment groups were mild."( Efficacy and safety of CH-1504, a metabolically stable antifolate, in patients with active rheumatoid arthritis: results of a phase II multicenter randomized study.
Hewitt, LA; Keystone, EC; Pedder, S; Shirinsky, VS; Simon, LS, 2011
)
0.37
"CH-1504 has comparable efficacy to MTX and is safe and well tolerated."( Efficacy and safety of CH-1504, a metabolically stable antifolate, in patients with active rheumatoid arthritis: results of a phase II multicenter randomized study.
Hewitt, LA; Keystone, EC; Pedder, S; Shirinsky, VS; Simon, LS, 2011
)
0.37
" Outcomes measured included adverse events (AEs), pharmacokinetics, and radiologic response."( Pralatrexate with vitamin supplementation in patients with previously treated, advanced non-small cell lung cancer: safety and efficacy in a phase 1 trial.
Azzoli, CG; Dunne, M; Ginsberg, M; Huntington, M; James, L; Kris, MG; Krug, LM; May, J; Miller, V; Patel, JD; Saunders, M; Sirotnak, FM; Subzwari, S; Tyson, L, 2011
)
0.37
" In addition, the authors highlight pralatrexate-associated adverse effects and safety concerns."( Pralatrexate : evaluation of clinical efficacy and toxicity in T-cell lymphoma.
Dasanu, CA; Shimanovsky, A, 2013
)
0.39
"Balancing efficacy and safety of drugs is key for successful cancer therapy, as adverse reactions can prohibit the use of efficacious treatments."( Preemptive leucovorin administration minimizes pralatrexate toxicity without sacrificing efficacy.
Geskin, LJ; Koch, E; Story, SK, 2013
)
0.39
" In the present study, the potential developmental toxicity of drugs was divided into three classes (1: non-developmentally toxic, 2: weakly developmentally toxic and 3: strongly developmentally toxic) according to the EST criteria."( A novel screening test to predict the developmental toxicity of drugs using human induced pluripotent stem cells.
Aikawa, N, 2020
)
0.56

Pharmacokinetics

gamma-methylene-10-deazaaminopterin (MDAM) is a unique antifolate structurally similar to methotrexate (MTX), in the treatment of patients with solid tumors. MDAM was administered intravenously for five consecutive days repeated every 21 days.

ExcerptReferenceRelevance
" Efficient use of pharmacokinetic models may help in reducing these unwanted actions of methotrexate in cancer chemotherapy."( Methotrexate. I. Pharmacology and pharmacokinetics.
Lippens, RJ, 1984
)
0.27
"The pharmacodynamic profiles of methotrexate (MTX) and 10-ethyl-10-deazaaminopterin (10-EdAM) were determined in three head and neck squamous cell carcinoma (HNSCC) cell lines."( Importance of pharmacodynamics in the in vitro antiproliferative activity of the antifolates methotrexate and 10-ethyl-10-deazaaminopterin against human head and neck squamous cell carcinoma.
Braakhuis, BJ; Jansen, G; Kegel, A; Noordhuis, P; Peters, GJ, 1993
)
0.72
" Because of laboratory data that suggests improved metabolism of AMT versus methotrexate (MTX) in lymphoblasts, we developed a phase I trial to determine the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), and pharmacokinetic profile of AMT."( Phase I and pharmacokinetic trial of aminopterin in patients with refractory malignancies.
Hum, M; Kamen, BA; Marling-Cason, M; Ratliff, AF; Rose, K; Wilson, J; Winick, N, 1998
)
0.57
"To determine the maximum tolerated dose (MTD) of gamma-methylene-10-deazaaminopterin (MDAM), a unique antifolate structurally similar to methotrexate (MTX), in the treatment of patients with solid tumors and to characterize toxicity and pharmacokinetic profiles of MDAM administered intravenously for five consecutive days repeated every 21 days."( Final results of a phase I and pharmacokinetic study of gamma-methylene-10-deazaaminopterin (MDAM) administered intravenously daily for five consecutive days in patients with solid tumors.
Abbruzzeese, J; Berghorn, E; Hausheer, F; Hoff, PM; Hutto, T; Johansen, M; Madden, T; Newman, RA; Ni, D; Zukowski, T, 2004
)
0.78
" Pharmacokinetic analyses were performed in 16 of the 18 patients receiving MDAM at doses of 80, 160, 240, 270 and 300 mg/m2."( Final results of a phase I and pharmacokinetic study of gamma-methylene-10-deazaaminopterin (MDAM) administered intravenously daily for five consecutive days in patients with solid tumors.
Abbruzzeese, J; Berghorn, E; Hausheer, F; Hoff, PM; Hutto, T; Johansen, M; Madden, T; Newman, RA; Ni, D; Zukowski, T, 2004
)
0.55
"MDAM is a novel antifolate with potential pharmacokinetic and safety advantages over MTX."( Final results of a phase I and pharmacokinetic study of gamma-methylene-10-deazaaminopterin (MDAM) administered intravenously daily for five consecutive days in patients with solid tumors.
Abbruzzeese, J; Berghorn, E; Hausheer, F; Hoff, PM; Hutto, T; Johansen, M; Madden, T; Newman, RA; Ni, D; Zukowski, T, 2004
)
0.55
" We compared the pharmacodynamic properties of AMT (given orally at 4 mg/m2 in two divided doses per week) and MTX (100 mg/m2 in four divided doses per week) among children with acute lymphoblastic leukemia."( Pharmacodynamic properties of methotrexate and Aminotrexate during weekly therapy.
Alcaraz, MJ; Cole, PD; Kamen, BA; Smith, AK; Tan, J; Zebala, JA, 2006
)
0.33
" However, the results of the pharmacokinetic analysis support the development of a new formulation to improve the bioavailability before further clinical studies are warranted."( Two single-center, double-blind, randomized, placebo-controlled, phase I studies to investigate the tolerability and pharmacokinetics of CH-1504, an antifolate, in healthy male subjects.
Adams, L; Boland, J; Hewitt, LA; Jurcevic, S; Mant, T; Szakacs, C, 2008
)
0.35
" Weight and methylmalonic acid (MMA) level were predictive of pharmacokinetic (PK) variability."( A population pharmacokinetic and pharmacodynamic evaluation of pralatrexate in patients with relapsed or refractory non-Hodgkin's or Hodgkin's lymphoma.
Duffull, SB; Fleisher, M; Hamlin, P; Horwitz, S; Mould, DR; Neylon, E; O'Connor, OA; Saunders, ME; Sirotnak, F; Sweeney, K, 2009
)
0.35

Compound-Compound Interactions

ExcerptReferenceRelevance
"Motivated by the observation of preclinical synergy, a Phase I dose escalation study of edatrexate in combination with a 3-h paclitaxel infusion was performed in patients with advanced breast cancer to determine the maximum tolerated dose (MTD) of edatrexate and the toxicities associated with this combination and to report preliminary observations of efficacy with this novel combination."( Phase I study of escalating doses of edatrexate in combination with paclitaxel in patients with metastatic breast cancer.
Baselga, J; D'Andrea, G; Fennelly, D; Gilewski, T; Hudis, C; Moynahan, ME; Norton, L; Raptis, G; Seidman, AD; Sklarin, N; Surbone, A; Templeton, MA; Theodoulou, M; Yao, TJ, 1999
)
0.3
" This Phase I study was designed to evaluate two schedules of administration of cisplatin in combination with escalating doses of edatrexate, in a population consisting mainly of patients with these two cancers."( Phase I and pharmacological study of two schedules of the antifolate edatrexate in combination with cisplatin.
Chronowski, G; Heelan, RT; Kris, MG; Laurie, SA; Pfister, DG; Pisters, KM; Sirotnak, FM; Tong, WP, 2001
)
0.31
" The aim of this phase I study was to determine the maximum-tolerated dose of pralatrexate when combined with probenecid given every 2 weeks in humans."( A phase I clinical pharmacologic study of pralatrexate in combination with probenecid in adults with advanced solid tumors.
Azzoli, CG; Fury, MG; Kemeny, N; Kris, MG; Krug, LM; Rizvi, NA; Sharma, S; Wu, N, 2006
)
0.33
"For patients with advanced solid tumors, the maximum-tolerated dose of this drug combination was pralatrexate 40 mg/m(2) and probenecid 140 mg/m(2)."( A phase I clinical pharmacologic study of pralatrexate in combination with probenecid in adults with advanced solid tumors.
Azzoli, CG; Fury, MG; Kemeny, N; Kris, MG; Krug, LM; Rizvi, NA; Sharma, S; Wu, N, 2006
)
0.33
"This study aimed to assess the long-term tolerability of pralatrexate alone or in combination with oral bexarotene for relapsed or refractory mycosis fungoides (MF)."( Pralatrexate alone or in combination with bexarotene: long-term tolerability in relapsed/refractory mycosis fungoides.
Duvic, M; Gangar, P; Talpur, R; Thompson, A, 2014
)
0.4
" During a second phase I/II dose-ranging combination trial, participants were treated with pralatrexate at 15 mg/m(2)/wk for 3 of 4 weeks combined with 150 to 300 mg/m(2) of daily oral bexarotene."( Pralatrexate alone or in combination with bexarotene: long-term tolerability in relapsed/refractory mycosis fungoides.
Duvic, M; Gangar, P; Talpur, R; Thompson, A, 2014
)
0.4
"Pralatrexate alone or in combination with low-dose oral bexarotene is well tolerated and capable of providing long-term responses in patients of advanced age with advanced-stage MF."( Pralatrexate alone or in combination with bexarotene: long-term tolerability in relapsed/refractory mycosis fungoides.
Duvic, M; Gangar, P; Talpur, R; Thompson, A, 2014
)
0.4
" To our knowledge, we report the first case using an MTX serum assay as a surrogate for PDX concentrations to avoid a potential drug-drug interaction with pralatrexate."( Pralatrexate Monitoring Using a Commercially Available Methotrexate Assay to Avoid Potential Drug Interactions.
Gilreath, JA; Halwani, AS; McPherson, JP; Sedillo, C; Vrontikis, A, 2016
)
0.43
" This phase 1 study investigated the safety and efficacy of pralatrexate in combination with bortezomib in adults with relapsed or refractory multiple myeloma."( A phase 1, open-label, dose-escalation study of pralatrexate in combination with bortezomib in patients with relapsed/refractory multiple myeloma.
Berube, C; Coutré, SE; Dinner, S; Dunn, TJ; Gotlib, J; Hao, Y; Liedtke, M; Medeiros, BC; Price, E, 2016
)
0.43
" A recent study disclosed that pralatrexate has a synergistic effect in combination with bortezomib."( Pralatrexate in Combination with Bortezomib for Relapsed or Refractory Peripheral T Cell Lymphoma in 5 Elderly Patients.
Ahn, JS; Cho, MS; Jung, SH; Jung, SY; Kim, HJ; Kim, YK; Lee, JJ; Lee, SS; Yang, DH, 2016
)
0.43

Bioavailability

Aminopterin deserves further study as a potent alternative to methotrexate. Complete bioavailability of aminopterin was confirmed, with a mean area under the curve of 0.

ExcerptReferenceRelevance
"28 hours and the oral bioavailability in 12 matched subjects was 83."( Phase I and pharmacokinetic trial of aminopterin in patients with refractory malignancies.
Hum, M; Kamen, BA; Marling-Cason, M; Ratliff, AF; Rose, K; Wilson, J; Winick, N, 1998
)
0.57
"We conclude that AMT has good oral bioavailability and that, when given on a q12 hour x two weekly schedule, the MTD is 2 mg/m2 with delayed LV rescue."( Phase I and pharmacokinetic trial of aminopterin in patients with refractory malignancies.
Hum, M; Kamen, BA; Marling-Cason, M; Ratliff, AF; Rose, K; Wilson, J; Winick, N, 1998
)
0.57
" With greater cellular accumulation and metabolism, more reliable bioavailability than methotrexate, and tolerable toxicity at this dose and schedule, aminopterin deserves further study as a potent alternative to methotrexate."( Phase II trial of oral aminopterin for adults and children with refractory acute leukemia.
Cate, S; Cole, PD; Drachtman, RA; Hawkins, DS; Holcenberg, J; Kamen, BA; Kelly, K; Larson, RA; Smith, AK, 2005
)
0.84
" However, the results of the pharmacokinetic analysis support the development of a new formulation to improve the bioavailability before further clinical studies are warranted."( Two single-center, double-blind, randomized, placebo-controlled, phase I studies to investigate the tolerability and pharmacokinetics of CH-1504, an antifolate, in healthy male subjects.
Adams, L; Boland, J; Hewitt, LA; Jurcevic, S; Mant, T; Szakacs, C, 2008
)
0.35
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" At a dosage of 6 mg/kg q1d X 5 against solid tumors, the relative tumor volumes (treated/control X 100%) were 12%/41% for Sarcoma 180, 16%/31% for Taper liver tumor, and 20%/30% for Ehrlich ascites carcinoma."( Antitumor properties of a new folate analog, 10-deaza-aminopterin, in mice.
DeGraw, JI; Dorick, DM; Moccio, DM; Sirotnak, FM, 1978
)
0.51
" These results suggest that this three-drug regimen may have synergistic antitumor effects, with a steep dose-response relationship, particularly with 10-EdAM."( Edatrexate improves the antitumor effects of cyclophosphamide and cisplatin against non-small cell lung cancer.
Dimery, IW; Fossella, FV; Glisson, BS; Hong, WK; Lee, JS; Libshitz, HI; Lippman, SM; Murphy, WK; Pang, AC; Shin, DM, 1991
)
0.28
" 10-Edam employed at this dosage and schedule was not effective as a treatment against advanced colorectal carcinoma."( Phase II trial of 10-Edam in patients with advanced colorectal carcinoma.
Israel, K; Kemeny, N; O'Hehir, M, 1990
)
0.28
" Despite the 2-fold attenuation of dosage required, antitumor activity of the combination (increased life span, 161%) was approximately twice that obtained with maximum tolerated doses of either agent alone and tumor-free, long-term survivors were obtained."( Intracavitary therapy of murine ovarian cancer with cis-diamminedichloroplatinum(II) and 10-ethyl-10-deazaaminopterin incorporating systemic leucovorin protection.
DeGraw, JI; Schmid, FA; Sirotnak, FM, 1989
)
0.49
" At the dosage and schedule used, 10-EDAM is an active agent in patients with NSCLC who are previously untreated with chemotherapy with a predicted response rate greater than or equal to 15% (P = ."( Phase II study of 10-ethyl-10-deaza-aminopterin in patients with stage III and IV non-small-cell lung cancer.
Burke, MT; Gralla, RJ; Heelan, RT; Kris, MG; Marks, LD; Shum, KY, 1988
)
0.55
" The dosage levels ranged from 5 to 120 mg/m2."( Phase I trial and clinical pharmacological evaluation of 10-ethyl-10-deazaaminopterin in adult patients with advanced cancer.
Fanucchi, MP; Farag, F; Gralla, RJ; Kinahan, JJ; Kris, MG; Marks, LD; O'Connell, JP; Wertheim, MS; Williams, L; Young, CW, 1988
)
0.51
" All two-drug combinations required attenuation to one-half the LD10 dosage for each."( Combination chemotherapy with a new folate analog: activity of 10-ethyl-10-deaza-aminopterin compared to methotrexate with 5-fluorouracil and alkylating agents against advanced metastatic disease in murine tumor models.
DeGraw, JI; Otter, GM; Schmid, FA; Sirotnak, FM,
)
0.36
"), K(m) or K(i), enzyme concentration, the concentration of substrate or inhibitor required for a half-maximal effect and standard errors of these parameters can be calculated from dose-response measurements; the concentration of each component of the system may be estimated also."( Steady-state enzyme kinetics with high-affinity substrates or inhibitors. A statistical treatment of dose-response curves.
Henderson, PJ, 1973
)
0.25
" Against L1210 in mice, the percent increase in life span at the LD10 dosage was +151% (methotrexate), +178% (10-deazaminopterin), +235% (10-methyl analogue), and +211% (10-ethyl analogue)."( Synthesis and antitumor activity of 10-alkyl-10-deazaminopterins. A convenient synthesis of 10-deazaminopterin.
Brown, VH; DeGraw, JI; Gaumont, Y; Kisliuk, RL; Sirotnak, FM; Tagawa, H, 1982
)
0.72
" Carboplatin was given as an outpatient on day 1 at a dosage based on the formula: Dose (mg/m2) = (0."( Phase II study of carboplatin and edatrexate (10-EdAM) with leucovorin rescue for patients with recurrent squamous cell carcinoma of the head and neck.
Benner, SE; Dimery, IW; Esparaz, B; Frenning, D; Guillory-Perez, C; Hong, WK; Huber, MH; Lippman, SM; Shirinian, M, 1994
)
0.29
" Combination therapy with EDX and vinca alkaloids required dosage attenuation but was still markedly more effective."( Effective combination therapy of metastatic murine solid tumors with edatrexate and the vinca alkaloids, vinblastine, navelbine and vindesine.
Otter, GM; Sirotnak, FM, 1994
)
0.29
" Nine dosage levels ranging from 120 to 3750 mg/m2 were explored."( High-dose edatrexate with oral leucovorin rescue: a phase I and clinical pharmacological study in adults with advanced cancer.
Bertino, JR; Densmore, CL; Fleisher, M; Grant, SC; Heelan, RT; Kris, MG; Krol, G; Miller, VA; Pfister, DG; Pisters, KM; Rigas, JR; Sirotnak, FM; Tong, W; Tyson, LB, 1996
)
0.29
" However, MTX concentrations in the cerebrospinal fluid after oral dosage are significantly greater than AMT."( Pharmacodynamic properties of methotrexate and Aminotrexate during weekly therapy.
Alcaraz, MJ; Cole, PD; Kamen, BA; Smith, AK; Tan, J; Zebala, JA, 2006
)
0.33
", weight or body surface area)-based dosing and that pretreatment with folic acid and vitamin B(12) might diminish the incidence and severity of mucositis."( A population pharmacokinetic and pharmacodynamic evaluation of pralatrexate in patients with relapsed or refractory non-Hodgkin's or Hodgkin's lymphoma.
Duffull, SB; Fleisher, M; Hamlin, P; Horwitz, S; Mould, DR; Neylon, E; O'Connor, OA; Saunders, ME; Sirotnak, F; Sweeney, K, 2009
)
0.35
" We defined each agent's clinical potency index (CPI) as the AUC achieved with standard pediatric dosing regimens divided by the in vitro IC50."( Clinical potency of methotrexate, aminopterin, talotrexin and pemetrexed in childhood leukemias.
Adamson, PC; Norris, RE, 2010
)
0.64
" No dose-response relationship was observed."( Efficacy and safety of CH-1504, a metabolically stable antifolate, in patients with active rheumatoid arthritis: results of a phase II multicenter randomized study.
Hewitt, LA; Keystone, EC; Pedder, S; Shirinsky, VS; Simon, LS, 2011
)
0.37
" A dose de-escalation strategy identified recommended pralatrexate dosing for patients with CTCL that demonstrated high activity, good rates of disease control, and an acceptable toxicity profile for continuous long-term dosing."( Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma.
Bartlett, NL; Delioukina, ML; Duvic, M; Fisher, DC; Foss, F; Horwitz, SM; Kim, YH; Koutsoukos, T; Lechowicz, MJ; Myskowski, PL; O'Connor, OA; Saunders, ME; Shustov, AR; Zain, JM, 2012
)
0.38
" The study was initiated with a dosing schedule of pralatrexate 190 mg/m(2) biweekly on a 4-week cycle with vitamin supplementation."( A phase II study of pralatrexate with vitamin B12 and folic acid supplementation for previously treated recurrent and/or metastatic head and neck squamous cell cancer.
Apollo, A; Cox, L; Fury, MG; Haque, S; Ho, AL; Lipson, BL; Lyo, JK; Pfister, DG; Sales, R; Seetharamu, N; Sherman, EJ; Sima, CS; Xiao, H, 2014
)
0.4
" It is not known how antifolate dose and dosing frequency affect efficacy in AD, but a primary mechanism is thought to involve the antifolate-mediated accumulation of 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR)."( LD-aminopterin in the canine homologue of human atopic dermatitis: a randomized, controlled trial reveals dosing factors affecting optimal therapy.
Griffin, CE; Kahn, SJ; Messinger, L; Mundell, A; Schuler, AD; Zebala, JA, 2014
)
1.02
" Twice-weekly dosing negated efficacy despite having the same daily and weekly dose as effective once-weekly regimens."( LD-aminopterin in the canine homologue of human atopic dermatitis: a randomized, controlled trial reveals dosing factors affecting optimal therapy.
Griffin, CE; Kahn, SJ; Messinger, L; Mundell, A; Schuler, AD; Zebala, JA, 2014
)
1.02
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
mutagenAn agent that increases the frequency of mutations above the normal background level, usually by interacting directly with DNA and causing it damage, including base substitution.
EC 1.5.1.3 (dihydrofolate reductase) inhibitorAn EC 1.5.1.* (oxidoreductase acting on donor CH-NH group, NAD(+) or NADP(+) as acceptor) inhibitor that interferes with the action of dihydrofolate reductase (EC 1.5.1.3).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
dicarboxylic acidAny carboxylic acid containing two carboxy groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (30)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency44.83563.189029.884159.4836AID1224846; AID1224894
SMAD family member 2Homo sapiens (human)Potency22.90220.173734.304761.8120AID1347035
SMAD family member 3Homo sapiens (human)Potency22.90220.173734.304761.8120AID1347035
TDP1 proteinHomo sapiens (human)Potency21.14460.000811.382244.6684AID686978; AID686979
AR proteinHomo sapiens (human)Potency22.80270.000221.22318,912.5098AID743035; AID743036; AID743042; AID743063
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency0.04870.001022.650876.6163AID1224838; AID1224893
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency31.32740.000214.376460.0339AID720691; AID720692
retinoid X nuclear receptor alphaHomo sapiens (human)Potency17.74160.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency0.10960.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency28.29880.375827.485161.6524AID743217; AID743220; AID743239
pregnane X nuclear receptorHomo sapiens (human)Potency22.71240.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency1.57110.000229.305416,493.5996AID743075; AID743080; AID743091
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency40.95560.001024.504861.6448AID743212; AID743215; AID743227
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency11.64410.001019.414170.9645AID743094; AID743140; AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency38.87020.023723.228263.5986AID743222; AID743223; AID743241
activating transcription factor 6Homo sapiens (human)Potency51.27160.143427.612159.8106AID1159516; AID1159519
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency51.271619.739145.978464.9432AID1159509; AID1159518
Histone H2A.xCricetulus griseus (Chinese hamster)Potency0.66550.039147.5451146.8240AID1224896
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency16.76800.000323.4451159.6830AID743065; AID743067
heat shock protein beta-1Homo sapiens (human)Potency3.85750.042027.378961.6448AID743210; AID743228
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency0.01010.000627.21521,122.0200AID743202; AID743219
Cellular tumor antigen p53Homo sapiens (human)Potency0.33660.002319.595674.0614AID651631; AID720552
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Dihydrofolate reductaseHomo sapiens (human)IC50 (µMol)0.02010.00060.87267.3000AID56809; AID56815; AID56955; AID56984; AID57067; AID57109
Dihydrofolate reductaseHomo sapiens (human)Ki0.00010.00000.37564.9000AID219254; AID57132; AID57140
Dihydrofolate reductaseMus musculus (house mouse)IC50 (µMol)0.02530.00200.99697.0000AID56740; AID57294; AID57296; AID57298; AID57303; AID57305
Dihydrofolate reductaseMus musculus (house mouse)Ki0.00000.00000.21713.9000AID57448; AID57454; AID57461
Dihydrofolate reductaseLacticaseibacillus caseiIC50 (µMol)0.00500.00130.26964.9000AID57944
Dihydrofolate reductaseEscherichia coli K-12IC50 (µMol)0.01100.00150.55126.8000AID57099
Solute carrier organic anion transporter family member 1A3Rattus norvegicus (Norway rat)Ki0.50000.50003.30008.2000AID681604
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Dihydrofolate reductaseMus musculus (house mouse)ID500.02110.00200.01640.0500AID57316; AID57440
Dihydrofolate reductaseLacticaseibacillus caseiID500.02700.00620.01620.0270AID57773
5-hydroxytryptamine receptor 2CRattus norvegicus (Norway rat)ID500.04000.04000.04500.0500AID57316
Folylpolyglutamate synthase, mitochondrialMus musculus (house mouse)Km8,800,010.00008.00008.00008.0000AID71200; AID71382
Folylpolyglutamate synthase, mitochondrialHomo sapiens (human)Km4.25910.40004.53447.3000AID282409; AID282577; AID282796; AID71356; AID71357; AID71359; AID71360; AID71516; AID71527; AID72165; AID72166
Folylpolyglutamate synthase, mitochondrialHomo sapiens (human)Vmax1.00000.82000.91001.0000AID71361
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (144)

Processvia Protein(s)Taxonomy
tetrahydrobiopterin biosynthetic processDihydrofolate reductaseHomo sapiens (human)
one-carbon metabolic processDihydrofolate reductaseHomo sapiens (human)
negative regulation of translationDihydrofolate reductaseHomo sapiens (human)
axon regenerationDihydrofolate reductaseHomo sapiens (human)
response to methotrexateDihydrofolate reductaseHomo sapiens (human)
dihydrofolate metabolic processDihydrofolate reductaseHomo sapiens (human)
tetrahydrofolate metabolic processDihydrofolate reductaseHomo sapiens (human)
tetrahydrofolate biosynthetic processDihydrofolate reductaseHomo sapiens (human)
folic acid metabolic processDihydrofolate reductaseHomo sapiens (human)
positive regulation of nitric-oxide synthase activityDihydrofolate reductaseHomo sapiens (human)
regulation of removal of superoxide radicalsDihydrofolate reductaseHomo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
10-formyltetrahydrofolate biosynthetic processDihydrofolate reductaseEscherichia coli K-12
response to xenobiotic stimulusDihydrofolate reductaseEscherichia coli K-12
folic acid biosynthetic processDihydrofolate reductaseEscherichia coli K-12
one-carbon metabolic processDihydrofolate reductaseEscherichia coli K-12
response to methotrexateDihydrofolate reductaseEscherichia coli K-12
tetrahydrofolate biosynthetic processDihydrofolate reductaseEscherichia coli K-12
response to antibioticDihydrofolate reductaseEscherichia coli K-12
dihydrofolate metabolic processDihydrofolate reductaseEscherichia coli K-12
folic acid metabolic processDihydrofolate reductaseEscherichia coli K-12
liver developmentFolylpolyglutamate synthase, mitochondrialHomo sapiens (human)
nucleobase-containing compound metabolic processFolylpolyglutamate synthase, mitochondrialHomo sapiens (human)
glutamate metabolic processFolylpolyglutamate synthase, mitochondrialHomo sapiens (human)
one-carbon metabolic processFolylpolyglutamate synthase, mitochondrialHomo sapiens (human)
folic acid-containing compound metabolic processFolylpolyglutamate synthase, mitochondrialHomo sapiens (human)
animal organ regenerationFolylpolyglutamate synthase, mitochondrialHomo sapiens (human)
folic acid metabolic processFolylpolyglutamate synthase, mitochondrialHomo sapiens (human)
tetrahydrofolylpolyglutamate biosynthetic processFolylpolyglutamate synthase, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (48)

Processvia Protein(s)Taxonomy
mRNA regulatory element binding translation repressor activityDihydrofolate reductaseHomo sapiens (human)
mRNA bindingDihydrofolate reductaseHomo sapiens (human)
dihydrofolate reductase activityDihydrofolate reductaseHomo sapiens (human)
folic acid bindingDihydrofolate reductaseHomo sapiens (human)
NADPH bindingDihydrofolate reductaseHomo sapiens (human)
sequence-specific mRNA bindingDihydrofolate reductaseHomo sapiens (human)
NADP bindingDihydrofolate reductaseHomo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
dihydrofolate reductase activityDihydrofolate reductaseEscherichia coli K-12
protein bindingDihydrofolate reductaseEscherichia coli K-12
folic acid bindingDihydrofolate reductaseEscherichia coli K-12
oxidoreductase activityDihydrofolate reductaseEscherichia coli K-12
NADP bindingDihydrofolate reductaseEscherichia coli K-12
methotrexate bindingDihydrofolate reductaseEscherichia coli K-12
dihydrofolic acid bindingDihydrofolate reductaseEscherichia coli K-12
NADP+ bindingDihydrofolate reductaseEscherichia coli K-12
NADPH bindingDihydrofolate reductaseEscherichia coli K-12
tetrahydrofolylpolyglutamate synthase activityFolylpolyglutamate synthase, mitochondrialHomo sapiens (human)
ATP bindingFolylpolyglutamate synthase, mitochondrialHomo sapiens (human)
metal ion bindingFolylpolyglutamate synthase, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (20)

Processvia Protein(s)Taxonomy
mitochondrionDihydrofolate reductaseHomo sapiens (human)
cytosolDihydrofolate reductaseHomo sapiens (human)
mitochondrionDihydrofolate reductaseHomo sapiens (human)
cytosolDihydrofolate reductaseMus musculus (house mouse)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
cytosolDihydrofolate reductaseEscherichia coli K-12
cytosolDihydrofolate reductaseEscherichia coli K-12
mitochondrial inner membraneFolylpolyglutamate synthase, mitochondrialHomo sapiens (human)
mitochondrial matrixFolylpolyglutamate synthase, mitochondrialHomo sapiens (human)
cytosolFolylpolyglutamate synthase, mitochondrialHomo sapiens (human)
cytoplasmFolylpolyglutamate synthase, mitochondrialHomo sapiens (human)
mitochondrionFolylpolyglutamate synthase, mitochondrialHomo sapiens (human)
cytosolFolylpolyglutamate synthase, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (198)

Assay IDTitleYearJournalArticle
AID71362Activity as substrate for recombinant human Folyl-polyglutamate synthase (rhFPGS) relative to aminopterin.2000Journal of medicinal chemistry, Aug-10, Volume: 43, Issue:16
Effect of C9-methyl substitution and C8-C9 conformational restriction on antifolate and antitumor activity of classical 5-substituted 2,4-diaminofuro[2,3-d]pyrimidines.
AID71505Ratio of Vmax and Km relative to AMT1989Journal of medicinal chemistry, Mar, Volume: 32, Issue:3
The 2-desamino and 2-desamino-2-methyl analogues of aminopterin do not inhibit dihydrofolate reductase but are potently toxic to tumor cells in culture.
AID66151Rate of influx of compound into the Ehrlich cells1981Journal of medicinal chemistry, Sep, Volume: 24, Issue:9
Folate analogues altered in the C9-N10 bridge region. 18. Synthesis and antitumor evaluation of 11-oxahomoaminopterin and related compounds.
AID22931First-order rate constant was determined1992Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23
A dideazatetrahydrofolate analogue lacking a chiral center at C-6, N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5- yl)ethyl]benzoyl]-L-glutamic acid, is an inhibitor of thymidylate synthase.
AID101081Inhibitory concentration against the growth of L1210 murine leukemia cells in tissue culture.1985Journal of medicinal chemistry, Jul, Volume: 28, Issue:7
Synthesis of the antileukemic agents 5,10-dideazaaminopterin and 5,10-dideaza-5,6,7,8-tetrahydroaminopterin.
AID71367Michaelis-Menten constant was determined against CCRF-CEM Folyl-polyglutamate synthase1993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Studies on analogues of classical antifolates bearing the naphthoyl group in place of benzoyl in the side chain.
AID282796Activity of human recombinant cytosolic FPGS2005Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23
Synthesis of N-{4-[(2,4-diamino-5-methyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)thio]benzoyl}-L-glutamic acid and N-{4-[(2-amino-4-oxo-5-methyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)thio]benzoyl}-L-glutamic acid as dual inhibitors of dihydrofol
AID234853Binding affinity was evaluated on CCRF-CEM human leukemia cell Folyl-polyglutamate synthetase1998Journal of medicinal chemistry, Apr-23, Volume: 41, Issue:9
Synthesis and biological activities of tricyclic conformationally restricted tetrahydropyrido annulated furo[2,3-d]pyrimidines as inhibitors of dihydrofolate reductases.
AID99179Inhibitory concentration against growth of L1210/R81 cell line1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
Methotrexate analogues. 33. N delta-acyl-N alpha-(4-amino-4-deoxypteroyl)-L-ornithine derivatives: synthesis and in vitro antitumor activity.
AID47440Tested for cell-growth inhibition against human leukemic lymphoblast CEM cells1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
Methotrexate analogues. 34. Replacement of the glutamate moiety in methotrexate and aminopterin by long-chain 2-aminoalkanedioic acids.
AID219254Inhibitory activity against Wild-type human DHFR1995Journal of medicinal chemistry, Mar-03, Volume: 38, Issue:5
2,4-Diamino-5-substituted-quinazolines as inhibitors of a human dihydrofolate reductase with a site-directed mutation at position 22 and of the dihydrofolate reductases from Pneumocystis carinii and Toxoplasma gondii.
AID57316Compound was evaluated for its antitumor activity by the inhibition of L1210 murine leukemia dihydrofolate reductase1984Journal of medicinal chemistry, May, Volume: 27, Issue:5
Methotrexate analogues. 19. Replacement of the glutamate side chain in classical antifolates by L-homocysteic acid and L-cysteic acid: effect on enzyme inhibition and antitumor activity.
AID71506Vmax of compound was derived from purified Folyl-polyglutamate synthase from mouse liver1989Journal of medicinal chemistry, Mar, Volume: 32, Issue:3
The 2-desamino and 2-desamino-2-methyl analogues of aminopterin do not inhibit dihydrofolate reductase but are potently toxic to tumor cells in culture.
AID1480213Cytotoxicity against human MCF7 cells assessed as decrease in cell viability after 48 hrs by MTS assay2018Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8
Synthesis and Evaluation of Hydrogen Peroxide Sensitive Prodrugs of Methotrexate and Aminopterin for the Treatment of Rheumatoid Arthritis.
AID57099Inhibition of dihydrofolate reductase in Escherichia coli1983Journal of medicinal chemistry, Aug, Volume: 26, Issue:8
Novel fluorinated antifolates. Enzyme inhibition and cytotoxicity studies on 2'- and 3'-fluoroaminopterin.
AID200581Tested for inhibitory concentration against human SCC25 cell line1994Journal of medicinal chemistry, Jul-08, Volume: 37, Issue:14
Synthesis and biological activity of N omega-hemiphthaloyl-alpha,omega- diaminoalkanoic acid analogues of aminopterin and 3',5-dichloroaminopterin.
AID56620Evaluated in vitro for ability to inhibit the Detroit 98 cell lines1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Synthesis and biological activity of an acyclic analogue of 5,6,7,8-tetrahydrofolic acid, N-[4-[[3-(2,4-diamino-1,6-dihydro-6-oxo-5- pyrimidinyl)propyl]amino]-benzoyl]-L-glutamic acid.
AID200596Cell growth inhibition against human squamous cell carcinoma (SCC25) line1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
Methotrexate analogues. 25. Chemical and biological studies on the gamma-tert-butyl esters of methotrexate and aminopterin.
AID1130120Inhibition of pigeon liver dihydrofolate reductase1979Journal of medicinal chemistry, Jul, Volume: 22, Issue:7
Analogues of methotrexate.
AID124656In vivo antitumor activity was evaluated against L1210 leukemia implanted mice by measuring 7-day weight change after intraperitoneal administration of compound at 0.12 mg/kg1984Journal of medicinal chemistry, May, Volume: 27, Issue:5
Methotrexate analogues. 19. Replacement of the glutamate side chain in classical antifolates by L-homocysteic acid and L-cysteic acid: effect on enzyme inhibition and antitumor activity.
AID22803Relative Vmax of compound was measured.1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Novel 2,4-diamino-5-substituted-pyrrolo[2,3-d]pyrimidines as classical and nonclassical antifolate inhibitors of dihydrofolate reductases.
AID409953Inhibition of mouse liver MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID282577Activity of human recombinant cytosolic FPGS2004Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27
Synthesis of classical, three-carbon-bridged 5-substituted furo[2,3-d]pyrimidine and 6-substituted pyrrolo[2,3-d]pyrimidine analogues as antifolates.
AID1130137Potency index, ratio of I50 for MTX to I50 for compound against pigeon liver dihydrofolate reductase1979Journal of medicinal chemistry, Jul, Volume: 22, Issue:7
Analogues of methotrexate.
AID131845Increase in life span of mice with L1210 leukemia cells at a dose of 1 mg/kg1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Methotrexate analogues. 28. Synthesis and biological evaluation of new gamma-monoamides of aminopterin and methotrexate.
AID22603Influx velocity of the compound1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Synthesis and antitumor activity of 10-alkyl-10-deazaminopterins. A convenient synthesis of 10-deazaminopterin.
AID98807In vitro membrane transport activity in L1210 cells in rodent1982Journal of medicinal chemistry, Jul, Volume: 25, Issue:7
10-Propargylaminopterin and alkyl homologues of methotrexate as inhibitors of folate metabolism.
AID681604TP_TRANSPORTER: inhibition of MTX uptake in OAT-K1-expressing MDCK cells2000The Journal of pharmacology and experimental therapeutics, Jun, Volume: 293, Issue:3
Trans-stimulation effects of folic acid derivatives on methotrexate transport by rat renal organic anion transporter, OAT-K1.
AID16875The efflux rate constant of the compound1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Synthesis and antitumor activity of 10-alkyl-10-deazaminopterins. A convenient synthesis of 10-deazaminopterin.
AID1653933Cytotoxicity against human HEK293 cells assessed as reduction in cell viability incubated for 48 hrs in presence of ROS scavenger pyruvate by Alamar blue assay2020Bioorganic & medicinal chemistry, 01-15, Volume: 28, Issue:2
Auxiliary in vitro and in vivo biological evaluation of hydrogen peroxide sensitive prodrugs of methotrexate and aminopterin for the treatment of rheumatoid arthritis.
AID1130121Cytotoxicity against human KB cells1979Journal of medicinal chemistry, Jul, Volume: 22, Issue:7
Analogues of methotrexate.
AID97900In vitro membrane transport activity in L1210 cells in rodent1982Journal of medicinal chemistry, Jul, Volume: 25, Issue:7
10-Propargylaminopterin and alkyl homologues of methotrexate as inhibitors of folate metabolism.
AID71491Catalytic rate constants (Vmax) was determined from mouse liver Folyl-polyglutamate synthase1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
Synthesis and antitumor activity of 5-deaza-5,6,7,8-tetrahydrofolic acid and its N10-substituted analogues.
AID71359Inhibitory activity of compound was measured for CCRF-CEM human leukemia cell Folyl-polyglutamate synthase1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Novel 2,4-diamino-5-substituted-pyrrolo[2,3-d]pyrimidines as classical and nonclassical antifolate inhibitors of dihydrofolate reductases.
AID98352Inhibitory concentration against growth of L1210 cell line1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
Methotrexate analogues. 33. N delta-acyl-N alpha-(4-amino-4-deoxypteroyl)-L-ornithine derivatives: synthesis and in vitro antitumor activity.
AID56955Inhibition of dihydrofolate reductase (DHFR) from human cells (WI-L2/M4).1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Synthesis and biological activity of methotrexate analogues with two acid groups and a hydrophobic aromatic ring in the side chain.
AID71357Activity as substrate for recombinant human Folyl-polyglutamate synthase (rhFPGS)2000Journal of medicinal chemistry, Aug-10, Volume: 43, Issue:16
Effect of C9-methyl substitution and C8-C9 conformational restriction on antifolate and antitumor activity of classical 5-substituted 2,4-diaminofuro[2,3-d]pyrimidines.
AID1653934Cytotoxicity against human HEK293 cells assessed as reduction in cell viability incubated for 48 hrs in absence of ROS scavenger pyruvate by Alamar blue assay2020Bioorganic & medicinal chemistry, 01-15, Volume: 28, Issue:2
Auxiliary in vitro and in vivo biological evaluation of hydrogen peroxide sensitive prodrugs of methotrexate and aminopterin for the treatment of rheumatoid arthritis.
AID57448Compound was evaluated for inhibitory effect on dihydrofolate reductase (DHFR) from L1210 cells at Inhibitory constant (n=3)1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Syntheses and antifolate activity of 5-methyl-5-deaza analogues of aminopterin, methotrexate, folic acid, and N10-methylfolic acid.
AID94706Evaluated for reversal of L cell inhibition, where reversal of toxicity was evaluated by the addition of Thymidine (20 uM)1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Synthesis and biological activity of an acyclic analogue of 5,6,7,8-tetrahydrofolic acid, N-[4-[[3-(2,4-diamino-1,6-dihydro-6-oxo-5- pyrimidinyl)propyl]amino]-benzoyl]-L-glutamic acid.
AID100447Compound was tested for its inhibitory concentration to inhibit the growth of wild type L1210 cells.1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Methotrexate analogues. 28. Synthesis and biological evaluation of new gamma-monoamides of aminopterin and methotrexate.
AID524792Antiplasmodial activity against Plasmodium falciparum D10 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID282798Ratio of Vmax relative to amphotericin to Km of human recombinant cytosolic FPGS2005Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23
Synthesis of N-{4-[(2,4-diamino-5-methyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)thio]benzoyl}-L-glutamic acid and N-{4-[(2-amino-4-oxo-5-methyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)thio]benzoyl}-L-glutamic acid as dual inhibitors of dihydrofol
AID56809Inhibition of dihydrofolate reductase in HeLa cells1983Journal of medicinal chemistry, Aug, Volume: 26, Issue:8
Novel fluorinated antifolates. Enzyme inhibition and cytotoxicity studies on 2'- and 3'-fluoroaminopterin.
AID56741Compound was tested for inhibition of the enzyme DiHydroFolate Reductase (DHFR) from murine L1210 leukemia cells1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Methotrexate analogues. 28. Synthesis and biological evaluation of new gamma-monoamides of aminopterin and methotrexate.
AID47282Cell growth inhibition against CEM cell from human leukemic lymphoblasts1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
Methotrexate analogues. 25. Chemical and biological studies on the gamma-tert-butyl esters of methotrexate and aminopterin.
AID99181Tested for cell-growth inhibition against mouse leukemic L1210/R81 cells1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
Methotrexate analogues. 34. Replacement of the glutamate moiety in methotrexate and aminopterin by long-chain 2-aminoalkanedioic acids.
AID71349Relative Vmax for its activation for Hog Liver Folyl-polyglutamate synthase was determined1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Synthesis and biological activity of an acyclic analogue of 5,6,7,8-tetrahydrofolic acid, N-[4-[[3-(2,4-diamino-1,6-dihydro-6-oxo-5- pyrimidinyl)propyl]amino]-benzoyl]-L-glutamic acid.
AID20346Activity relative to saturating aminopterine at 100 uM against CCRF-CEM Folyl-polyglutamate synthetase1993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Studies on analogues of classical antifolates bearing the naphthoyl group in place of benzoyl in the side chain.
AID44022Growth inhibition of CCRF-CEM human leukemic lymphoblasts2000Journal of medicinal chemistry, Apr-20, Volume: 43, Issue:8
Analogues of the potent nonpolyglutamatable antifolate N(alpha)-(4-amino-4-deoxypteroyl)-N(delta)-hemiphthaloyl-L-ornithine (PT523) with modifications in the side chain, p-aminobenzoyl moiety, or 9,10-bridge: synthesis and in vitro antitumor activity.
AID23337Relative maximum volume distribution of the compound.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Folic acid analogues lacking the 2-carbon are substrates for folylpolyglutamate synthetase and inhibit cell growth.
AID57296Inhibition of dihydrofolate reductase (DHFR) from murine leukemia cells1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
Methotrexate analogues. 33. N delta-acyl-N alpha-(4-amino-4-deoxypteroyl)-L-ornithine derivatives: synthesis and in vitro antitumor activity.
AID98147Compound was tested for its ability to inhibit growth of L1210 mouse leukemia cells1986Journal of medicinal chemistry, May, Volume: 29, Issue:5
Methotrexate analogues. 26. Inhibition of dihydrofolate reductase and folylpolyglutamate synthetase activity and in vitro tumor cell growth by methotrexate and aminopterin analogues containing a basic amino acid side chain.
AID121086In vivo antitumor activity was evaluated against L1210 leukemia implanted mice by measuring number of survival days after intraperitoneal administration of compound at 0.24 mg/kg at a range of 12-201984Journal of medicinal chemistry, May, Volume: 27, Issue:5
Methotrexate analogues. 19. Replacement of the glutamate side chain in classical antifolates by L-homocysteic acid and L-cysteic acid: effect on enzyme inhibition and antitumor activity.
AID71493First order catalytic rate constants (k) was determined from mouse liver Folyl-polyglutamate synthase1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
Synthesis and antitumor activity of 5-deaza-5,6,7,8-tetrahydrofolic acid and its N10-substituted analogues.
AID124655In vivo antitumor activity was evaluated against L1210 leukemia implanted mice by measuring 7-day weight change after intraperitoneal administration of compound at 0.06 mg/kg1984Journal of medicinal chemistry, May, Volume: 27, Issue:5
Methotrexate analogues. 19. Replacement of the glutamate side chain in classical antifolates by L-homocysteic acid and L-cysteic acid: effect on enzyme inhibition and antitumor activity.
AID98918Inhibitory concentration of compound in growth of L-1210 cells1981Journal of medicinal chemistry, Sep, Volume: 24, Issue:9
Folate analogues altered in the C9-N10 bridge region. 18. Synthesis and antitumor evaluation of 11-oxahomoaminopterin and related compounds.
AID56815Ability to inhibit purified Dihydrofolate reductase from human leukemic lymphoblasts was determined spectrophotometrically at 340 nM.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Analogues of methotrexate and aminopterin with gamma-methylene and gamma-cyano substitution of the glutamate side chain: synthesis and in vitro biological activity.
AID98132Compound was evaluated for inhibitory effect on growth of L1210 cells at IC50 (n=4)1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Syntheses and antifolate activity of 5-methyl-5-deaza analogues of aminopterin, methotrexate, folic acid, and N10-methylfolic acid.
AID71383Apparent catalytic rate constants (Km) owas determined from mouse liver Folyl-polyglutamate synthase1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
Synthesis and antitumor activity of 5-deaza-5,6,7,8-tetrahydrofolic acid and its N10-substituted analogues.
AID231102Ratio of app Km to ral Vmax1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Synthesis and biological activity of an acyclic analogue of 5,6,7,8-tetrahydrofolic acid, N-[4-[[3-(2,4-diamino-1,6-dihydro-6-oxo-5- pyrimidinyl)propyl]amino]-benzoyl]-L-glutamic acid.
AID200601Cell growth inhibition against human squamous cell carcinoma (SCC25/R1) line1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
Methotrexate analogues. 25. Chemical and biological studies on the gamma-tert-butyl esters of methotrexate and aminopterin.
AID71361Activity of compound calculated as maximum activity of substrate for human Folyl-polyglutamate synthase relative to the maximum activity for aminopterin2003Journal of medicinal chemistry, Feb-13, Volume: 46, Issue:4
Design, synthesis, and biological activities of classical N-[4-[2-(2-amino-4-ethylpyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid and its 6-methyl derivative as potential dual inhibitors of thymidylate synthase and dihydrofolate reductase and
AID121085In vivo antitumor activity was evaluated against L1210 leukemia implanted mice by measuring number of survival days after intraperitoneal administration of compound at 0.12 mg/kg at a range of 12-151984Journal of medicinal chemistry, May, Volume: 27, Issue:5
Methotrexate analogues. 19. Replacement of the glutamate side chain in classical antifolates by L-homocysteic acid and L-cysteic acid: effect on enzyme inhibition and antitumor activity.
AID43721Inhibitory activity against uptake of [3H]MTX by human leukemia cells (CCRF-CEM)1996Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1
Synthesis and biological evaluation of DL-4,4-difluoroglutamic acid and DL-gamma,gamma-difluoromethotrexate.
AID57136Inhibition constant (Ki) was determined in HeLa cells towards dihydrofolate reductase; ND is defined as no data1983Journal of medicinal chemistry, Aug, Volume: 26, Issue:8
Novel fluorinated antifolates. Enzyme inhibition and cytotoxicity studies on 2'- and 3'-fluoroaminopterin.
AID71382The apparent Km of compound as a substrate for partially purified mouse liver Folyl-polyglutamate synthase1989Journal of medicinal chemistry, Mar, Volume: 32, Issue:3
(6R,6S)-5,8,10-trideaza-5,6,7,8-tetrahydrofolate and 6(R,6S)-5,8,10-trideaza-5,6,7,8-tetrahydropteroyl-L-ornithine as potential antifolates and antitumor agents.
AID71527Activity as substrate for recombinant human folyl-poly-glutamate synthase (FPGS).2000Journal of medicinal chemistry, Oct-19, Volume: 43, Issue:21
Design, synthesis, and X-ray crystal structure of a potent dual inhibitor of thymidylate synthase and dihydrofolate reductase as an antitumor agent.
AID110835In vivo antitumor activity was evaluated against L1210 leukemia implanted mice by measuring percent increase in life span after intraperitoneal administration of compound at 0.06 mg/kg1984Journal of medicinal chemistry, May, Volume: 27, Issue:5
Methotrexate analogues. 19. Replacement of the glutamate side chain in classical antifolates by L-homocysteic acid and L-cysteic acid: effect on enzyme inhibition and antitumor activity.
AID282797Activity of human recombinant cytosolic FPGS relative to aminopterin2005Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23
Synthesis of N-{4-[(2,4-diamino-5-methyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)thio]benzoyl}-L-glutamic acid and N-{4-[(2-amino-4-oxo-5-methyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)thio]benzoyl}-L-glutamic acid as dual inhibitors of dihydrofol
AID99050Compound was evaluated for the efflux (K) mediated transport with respect to L1210 cells1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Syntheses and antifolate activity of 5-methyl-5-deaza analogues of aminopterin, methotrexate, folic acid, and N10-methylfolic acid.
AID57294Compound was tested for its ability to inhibit purified dihydrofolate reductase(DHFR) from L1210/R81 cells1986Journal of medicinal chemistry, May, Volume: 29, Issue:5
Methotrexate analogues. 26. Inhibition of dihydrofolate reductase and folylpolyglutamate synthetase activity and in vitro tumor cell growth by methotrexate and aminopterin analogues containing a basic amino acid side chain.
AID71375Compound was tested for its ability to inhibit Folyl-polyglutamate synthase from mouse liver1986Journal of medicinal chemistry, May, Volume: 29, Issue:5
Methotrexate analogues. 26. Inhibition of dihydrofolate reductase and folylpolyglutamate synthetase activity and in vitro tumor cell growth by methotrexate and aminopterin analogues containing a basic amino acid side chain.
AID728624Inhibition of Clostridium botulinum recombinant neurotoxin A light chain using SNAPtide as substrate at 10 uM after 1 hr by FRET assay relative to control2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Paclitaxel is an inhibitor and its boron dipyrromethene derivative is a fluorescent recognition agent for botulinum neurotoxin subtype A.
AID236271Km (FPGS substrate activity) for recombinant human FPGS2005Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16
Synthesis of classical, four-carbon bridged 5-substituted furo[2,3-d]pyrimidine and 6-substituted pyrrolo[2,3-d]pyrimidine analogues as antifolates.
AID97092Compound was evaluated for rate of anabolism to polyglutamate accumulation in L1210 cells1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Syntheses and antifolate activity of 5-methyl-5-deaza analogues of aminopterin, methotrexate, folic acid, and N10-methylfolic acid.
AID120946In vivo antitumor activity was evaluated against L1210 leukemia implanted mice by measuring T/C median after intraperitoneal administration of compound at 0.24 mg/kg; T/C median=19/81984Journal of medicinal chemistry, May, Volume: 27, Issue:5
Methotrexate analogues. 19. Replacement of the glutamate side chain in classical antifolates by L-homocysteic acid and L-cysteic acid: effect on enzyme inhibition and antitumor activity.
AID200609Cell growth inhibition against human squamous cell carcinoma (SCC78/R1) line1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
Methotrexate analogues. 25. Chemical and biological studies on the gamma-tert-butyl esters of methotrexate and aminopterin.
AID216095Compound was evaluated for cell growth inhibition of human (WI-L2) leukemic cells.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis and biological activity of the 2-desamino and 2-desamino-2-methyl analogues of aminopterin and methotrexate.
AID409955Inhibition of mouse liver MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1480219Antiarthritic activity in collagen-induced DBA/1J mouse arthritis model assessed as decrease in incidence of arthritis at 6.8 mg/kg, ip administered daily for 2 weeks starting on day 27 post first immunization measured thrice per week during compound dosi2018Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8
Synthesis and Evaluation of Hydrogen Peroxide Sensitive Prodrugs of Methotrexate and Aminopterin for the Treatment of Rheumatoid Arthritis.
AID46810Cell growth inhibition against CEM/MTX cell from human leukemic lymphoblasts1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
Methotrexate analogues. 25. Chemical and biological studies on the gamma-tert-butyl esters of methotrexate and aminopterin.
AID94567Evaluated for reversal of L cell inhibition, where reversal of toxicity was evaluated by the addition of Hypoxanthine (37 uM)1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Synthesis and biological activity of an acyclic analogue of 5,6,7,8-tetrahydrofolic acid, N-[4-[[3-(2,4-diamino-1,6-dihydro-6-oxo-5- pyrimidinyl)propyl]amino]-benzoyl]-L-glutamic acid.
AID282409Activity of human recombinant FPGS2004Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27
Benzoyl ring halogenated classical 2-amino-6-methyl-3,4-dihydro-4-oxo-5-substituted thiobenzoyl-7H-pyrrolo[2,3-d]pyrimidine antifolates as inhibitors of thymidylate synthase and as antitumor agents.
AID71516Binding affinity was evaluated on CCRF-CEM human leukemia cell folyl-poly-glutamate synthetase.1998Journal of medicinal chemistry, Apr-23, Volume: 41, Issue:9
Synthesis and biological activities of tricyclic conformationally restricted tetrahydropyrido annulated furo[2,3-d]pyrimidines as inhibitors of dihydrofolate reductases.
AID96581Compound was evaluated for the influx (Km) mediated transport with respect to L1210 cells1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Syntheses and antifolate activity of 5-methyl-5-deaza analogues of aminopterin, methotrexate, folic acid, and N10-methylfolic acid.
AID1480223Antiarthritic activity in collagen-induced DBA/1J mouse arthritis model assessed as reduction of macroscopic score at 6.8 mg/kg, ip administered daily for 2 weeks starting on day 27 post first immunization measured thrice per week during compound dosing r2018Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8
Synthesis and Evaluation of Hydrogen Peroxide Sensitive Prodrugs of Methotrexate and Aminopterin for the Treatment of Rheumatoid Arthritis.
AID71504Kinetic constant of compound was derived from purified Folyl-polyglutamate synthase from mouse liver1989Journal of medicinal chemistry, Mar, Volume: 32, Issue:3
The 2-desamino and 2-desamino-2-methyl analogues of aminopterin do not inhibit dihydrofolate reductase but are potently toxic to tumor cells in culture.
AID71346Apparent Km in uM for its activation for Hog Liver Folyl-polyglutamate synthase was determined1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Synthesis and biological activity of an acyclic analogue of 5,6,7,8-tetrahydrofolic acid, N-[4-[[3-(2,4-diamino-1,6-dihydro-6-oxo-5- pyrimidinyl)propyl]amino]-benzoyl]-L-glutamic acid.
AID200610Cell growth inhibition against human squamous cell carcinoma (SCC78) line1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
Methotrexate analogues. 25. Chemical and biological studies on the gamma-tert-butyl esters of methotrexate and aminopterin.
AID94568Evaluated for reversal of L cell inhibition, where reversal of toxicity was evaluated by the addition of Leucovorin (0.2 uM)1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Synthesis and biological activity of an acyclic analogue of 5,6,7,8-tetrahydrofolic acid, N-[4-[[3-(2,4-diamino-1,6-dihydro-6-oxo-5- pyrimidinyl)propyl]amino]-benzoyl]-L-glutamic acid.
AID98127Cell growth inhibition against mouse leukemia L1210 cells1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
Methotrexate analogues. 25. Chemical and biological studies on the gamma-tert-butyl esters of methotrexate and aminopterin.
AID46811Tested for cell-growth inhibition against human leukemic lymphoblast CEM/MTX cells1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
Methotrexate analogues. 34. Replacement of the glutamate moiety in methotrexate and aminopterin by long-chain 2-aminoalkanedioic acids.
AID57944Inhibition of dihydrofolate reductase in Lactobacillus casei1983Journal of medicinal chemistry, Aug, Volume: 26, Issue:8
Novel fluorinated antifolates. Enzyme inhibition and cytotoxicity studies on 2'- and 3'-fluoroaminopterin.
AID409954Inhibition of mouse brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID57286Tested in vitro for relative activity against CCRF-CEM human Leukemic lymphoblast by using DHFR as primary target1994Journal of medicinal chemistry, Jul-08, Volume: 37, Issue:14
Synthesis and biological activity of N omega-hemiphthaloyl-alpha,omega- diaminoalkanoic acid analogues of aminopterin and 3',5-dichloroaminopterin.
AID94566Evaluated in vitro for ability to inhibit the L cell lines.1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Synthesis and biological activity of an acyclic analogue of 5,6,7,8-tetrahydrofolic acid, N-[4-[[3-(2,4-diamino-1,6-dihydro-6-oxo-5- pyrimidinyl)propyl]amino]-benzoyl]-L-glutamic acid.
AID120944In vivo antitumor activity was evaluated against L1210 leukemia implanted mice by measuring T/C median after intraperitoneal administration of compound at 0.06 mg/kg; T/C median=12/81984Journal of medicinal chemistry, May, Volume: 27, Issue:5
Methotrexate analogues. 19. Replacement of the glutamate side chain in classical antifolates by L-homocysteic acid and L-cysteic acid: effect on enzyme inhibition and antitumor activity.
AID100659Compound was evaluated for its cytotoxicity against the L1210 murine leukemia cell culture1984Journal of medicinal chemistry, May, Volume: 27, Issue:5
Methotrexate analogues. 19. Replacement of the glutamate side chain in classical antifolates by L-homocysteic acid and L-cysteic acid: effect on enzyme inhibition and antitumor activity.
AID57132Compound was evaluated for the inhibition of Dihydrofolate reductase at concentration ranged from 0.15-0.50 uM1998Journal of medicinal chemistry, Dec-17, Volume: 41, Issue:26
Synthesis and potent antifolate activity and cytotoxicity of B-ring deaza analogues of the nonpolyglutamatable dihydrofolate reductase inhibitor Nalpha-(4-amino-4-deoxypteroyl)-Ndelta-hemiphthaloyl- L-ornithine (PT523).
AID1653931Cytotoxicity against human HL60 cells assessed reduction in cell viability incubated for 48 hrs in presence of ROS scavenger pyruvate by Alamar blue assay2020Bioorganic & medicinal chemistry, 01-15, Volume: 28, Issue:2
Auxiliary in vitro and in vivo biological evaluation of hydrogen peroxide sensitive prodrugs of methotrexate and aminopterin for the treatment of rheumatoid arthritis.
AID56740Compound was tested for its inhibitory concentration to inhibit the enzyme Dihydro Folate Reductase (DHFR) from murine L1210 leukemia cells.1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Methotrexate analogues. 28. Synthesis and biological evaluation of new gamma-monoamides of aminopterin and methotrexate.
AID57454In vitro inhibitory activity against L1210 dihydrofolate reductase in rodent neoplastic cells1982Journal of medicinal chemistry, Jul, Volume: 25, Issue:7
10-Propargylaminopterin and alkyl homologues of methotrexate as inhibitors of folate metabolism.
AID1653497Inhibition of Mycobacterium smegmatis ATCC 607 dihydrofolic reductase assessed as ratio of Km to Ki2019Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13
Insights of synthetic analogues of anti-leprosy agents.
AID234845Activity of substrate for human Folyl-polyglutamate synthetase was evaluated and compared to that of aminopterin (AMT)1998Journal of medicinal chemistry, Apr-23, Volume: 41, Issue:9
Synthesis and biological activities of tricyclic conformationally restricted tetrahydropyrido annulated furo[2,3-d]pyrimidines as inhibitors of dihydrofolate reductases.
AID1130138Potency index, ratio of ED50 for MTX to ED50 for compound against human KB cells1979Journal of medicinal chemistry, Jul, Volume: 22, Issue:7
Analogues of methotrexate.
AID216094Ability to inhibit WI-L2 murine leukemia tumor cell growth in culture after 48 hr of its exposure.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Analogues of methotrexate and aminopterin with gamma-methylene and gamma-cyano substitution of the glutamate side chain: synthesis and in vitro biological activity.
AID200603Cell growth inhibition against human squamous cell carcinoma (SCC68) line1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
Methotrexate analogues. 25. Chemical and biological studies on the gamma-tert-butyl esters of methotrexate and aminopterin.
AID200605Cell growth inhibition against human squamous cell carcinoma (SCC68/R1) line1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
Methotrexate analogues. 25. Chemical and biological studies on the gamma-tert-butyl esters of methotrexate and aminopterin.
AID1480201Kinetic solubility of the compound in DMSO/PBS mixture after 20 hrs by RP-UPLC-UV method2018Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8
Synthesis and Evaluation of Hydrogen Peroxide Sensitive Prodrugs of Methotrexate and Aminopterin for the Treatment of Rheumatoid Arthritis.
AID57109Tested in vitro for inhibitory concentration against CCRF-CEM human Leukemic lymphoblast by using DHFR as primary target1994Journal of medicinal chemistry, Jul-08, Volume: 37, Issue:14
Synthesis and biological activity of N omega-hemiphthaloyl-alpha,omega- diaminoalkanoic acid analogues of aminopterin and 3',5-dichloroaminopterin.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID57067Compound was evaluated for Dihydrofolate Reductase (DHFR) inhibition1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis and biological activity of the 2-desamino and 2-desamino-2-methyl analogues of aminopterin and methotrexate.
AID200586Tested for inhibitory concentration against SCC-VII murine squamous carcinoma cell line1994Journal of medicinal chemistry, Jul-08, Volume: 37, Issue:14
Synthesis and biological activity of N omega-hemiphthaloyl-alpha,omega- diaminoalkanoic acid analogues of aminopterin and 3',5-dichloroaminopterin.
AID72168folyl-poly-glutamate synthetase activity measured as Vmax; rel means relative2002Journal of medicinal chemistry, Apr-25, Volume: 45, Issue:9
Synthesis of N-[4-[1-ethyl-2-(2,4-diaminofuro[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid as an antifolate.
AID98023Inhibition of growth (cytotoxicity) of L1210 cell line in vitro1983Journal of medicinal chemistry, Aug, Volume: 26, Issue:8
Novel fluorinated antifolates. Enzyme inhibition and cytotoxicity studies on 2'- and 3'-fluoroaminopterin.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID121084In vivo antitumor activity was evaluated against L1210 leukemia implanted mice by measuring number of survival days after intraperitoneal administration of compound at 0.06 mg/kg at a range of 11-131984Journal of medicinal chemistry, May, Volume: 27, Issue:5
Methotrexate analogues. 19. Replacement of the glutamate side chain in classical antifolates by L-homocysteic acid and L-cysteic acid: effect on enzyme inhibition and antitumor activity.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID138382Compound was tested against weight change in mice with L1210 leukemia cells on 7 th Day at Dose 1 mg / kg1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Methotrexate analogues. 28. Synthesis and biological evaluation of new gamma-monoamides of aminopterin and methotrexate.
AID18069Apparent Km (Michaelis-Menten constant) of the compound.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Folic acid analogues lacking the 2-carbon are substrates for folylpolyglutamate synthetase and inhibit cell growth.
AID72165Ability to act as a substrate for human folyglutamate synthetase (FPGS)2002Journal of medicinal chemistry, Nov-07, Volume: 45, Issue:23
Synthesis of classical and nonclassical, partially restricted, linear, tricyclic 5-deaza antifolates.
AID1653498Antimicrobial activity against Mycobacterium smegmatis ATCC 6072019Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13
Insights of synthetic analogues of anti-leprosy agents.
AID57461Tested for inhibition of dihydrofolate reductase enzyme from mouse1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Synthesis and antitumor activity of 10-alkyl-10-deazaminopterins. A convenient synthesis of 10-deazaminopterin.
AID99177Compound was tested for its ability to inhibit growth of L1210/R81 cells1986Journal of medicinal chemistry, May, Volume: 29, Issue:5
Methotrexate analogues. 26. Inhibition of dihydrofolate reductase and folylpolyglutamate synthetase activity and in vitro tumor cell growth by methotrexate and aminopterin analogues containing a basic amino acid side chain.
AID1480212Cytotoxicity against human NCI-H460 cells assessed as decrease in cell viability after 48 hrs by MTS assay2018Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8
Synthesis and Evaluation of Hydrogen Peroxide Sensitive Prodrugs of Methotrexate and Aminopterin for the Treatment of Rheumatoid Arthritis.
AID99183Cell growth inhibition against mouse leukemia L1210/R81 cells1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
Methotrexate analogues. 25. Chemical and biological studies on the gamma-tert-butyl esters of methotrexate and aminopterin.
AID131839Increase in life span of mice with L1210 leukemia cells at a dose of 0.5 mg/kg1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Methotrexate analogues. 28. Synthesis and biological evaluation of new gamma-monoamides of aminopterin and methotrexate.
AID282415Ratio of relative Vmax to Km of human recombinant FPGS2004Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27
Benzoyl ring halogenated classical 2-amino-6-methyl-3,4-dihydro-4-oxo-5-substituted thiobenzoyl-7H-pyrrolo[2,3-d]pyrimidine antifolates as inhibitors of thymidylate synthase and as antitumor agents.
AID71363Vmax value for substrate activity against CCRF-CEM human leukemia cell Folyl-polyglutamate synthase1995Journal of medicinal chemistry, Sep-15, Volume: 38, Issue:19
Effect of bridge region variation on antifolate and antitumor activity of classical 5-substituted 2,4-diaminofuro[2,3-d]pyrimidines.
AID94705Evaluated for reversal of L cell inhibition, where reversal of toxicity was evaluated by the addition of Thymidine + Hypoxanthine1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Synthesis and biological activity of an acyclic analogue of 5,6,7,8-tetrahydrofolic acid, N-[4-[[3-(2,4-diamino-1,6-dihydro-6-oxo-5- pyrimidinyl)propyl]amino]-benzoyl]-L-glutamic acid.
AID1653936Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs in absence of ROS scavenger pyruvate by Alamar blue assay2020Bioorganic & medicinal chemistry, 01-15, Volume: 28, Issue:2
Auxiliary in vitro and in vivo biological evaluation of hydrogen peroxide sensitive prodrugs of methotrexate and aminopterin for the treatment of rheumatoid arthritis.
AID1130123Antitumor activity against mouse L1210 cells transfected in mouse assessed as increase in life span at 0.67 mg/kg, ip qd from day 1 to day 9 relative to control1979Journal of medicinal chemistry, Jul, Volume: 22, Issue:7
Analogues of methotrexate.
AID57773Inhibitory activity tested against dihydrofolate reductase from Lactobacillus casei1982Journal of medicinal chemistry, Dec, Volume: 25, Issue:12
Methotrexate analogues. 16. Importance of the side-chain amide carbonyl group as a structural determinant of biological activity.
AID99558Inhibition constant (Ki) was determined in Lactobacillus casei1983Journal of medicinal chemistry, Aug, Volume: 26, Issue:8
Novel fluorinated antifolates. Enzyme inhibition and cytotoxicity studies on 2'- and 3'-fluoroaminopterin.
AID234488ratio of vmax to Km2000Journal of medicinal chemistry, Aug-10, Volume: 43, Issue:16
Effect of C9-methyl substitution and C8-C9 conformational restriction on antifolate and antitumor activity of classical 5-substituted 2,4-diaminofuro[2,3-d]pyrimidines.
AID57440Inhibitory tested against Dihydrofolate reductase enzyme from L1210 mouse leukemia cells using [3H]methotrexate as a radioligand1982Journal of medicinal chemistry, Dec, Volume: 25, Issue:12
Methotrexate analogues. 16. Importance of the side-chain amide carbonyl group as a structural determinant of biological activity.
AID98130Compound was evaluated for cell growth inhibition of murine (L1210) leukemic cells1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis and biological activity of the 2-desamino and 2-desamino-2-methyl analogues of aminopterin and methotrexate.
AID1137096Antitumor activity against mouse L1210 cells allografted in mouse assessed as increase in life span at 0.18 mg/kg, sc administered daily up to death started on day 5 post tumor implantation relative to control1977Journal of medicinal chemistry, Jul, Volume: 20, Issue:7
Methotrexate analogues. 8. Synthesis and biological evaluation of bisamide derivatives as potential prodrugs.
AID57305Tested for inhibition against purified Dihydrofolate reductase from L1210 murine leukemia cells1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
Methotrexate analogues. 34. Replacement of the glutamate moiety in methotrexate and aminopterin by long-chain 2-aminoalkanedioic acids.
AID97896Rate of influx into the L1210 cells1981Journal of medicinal chemistry, Sep, Volume: 24, Issue:9
Folate analogues altered in the C9-N10 bridge region. 18. Synthesis and antitumor evaluation of 11-oxahomoaminopterin and related compounds.
AID1653932Cytotoxicity against human HL60 cells assessed as reduction in cell viability incubated for 48 hrs in absence of ROS scavenger pyruvate by Alamar blue assay2020Bioorganic & medicinal chemistry, 01-15, Volume: 28, Issue:2
Auxiliary in vitro and in vivo biological evaluation of hydrogen peroxide sensitive prodrugs of methotrexate and aminopterin for the treatment of rheumatoid arthritis.
AID110837In vivo antitumor activity was evaluated against L1210 leukemia implanted mice by measuring percent increase in life span after intraperitoneal administration of compound at 0.24 mg/kg1984Journal of medicinal chemistry, May, Volume: 27, Issue:5
Methotrexate analogues. 19. Replacement of the glutamate side chain in classical antifolates by L-homocysteic acid and L-cysteic acid: effect on enzyme inhibition and antitumor activity.
AID234747Selectivity ratio of Ki value against mutant DHFR and Wild-type DHFR1995Journal of medicinal chemistry, Mar-03, Volume: 38, Issue:5
2,4-Diamino-5-substituted-quinazolines as inhibitors of a human dihydrofolate reductase with a site-directed mutation at position 22 and of the dihydrofolate reductases from Pneumocystis carinii and Toxoplasma gondii.
AID228545Michaelis constant of compound was determined from affinity towards carrier component of transport mechanism1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Synthesis and antitumor activity of 10-alkyl-10-deazaminopterins. A convenient synthesis of 10-deazaminopterin.
AID124657In vivo antitumor activity was evaluated against L1210 leukemia implanted mice by measuring 7-day weight change after intraperitoneal administration of compound at 0.24 mg/kg1984Journal of medicinal chemistry, May, Volume: 27, Issue:5
Methotrexate analogues. 19. Replacement of the glutamate side chain in classical antifolates by L-homocysteic acid and L-cysteic acid: effect on enzyme inhibition and antitumor activity.
AID138381Compound was tested against weight change in mice with L1210 leukemia cells on 7 th Day at Dose 0.5 mg / kg1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Methotrexate analogues. 28. Synthesis and biological evaluation of new gamma-monoamides of aminopterin and methotrexate.
AID72166folyl-poly-glutamate synthetase activity measured as Km2002Journal of medicinal chemistry, Apr-25, Volume: 45, Issue:9
Synthesis of N-[4-[1-ethyl-2-(2,4-diaminofuro[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid as an antifolate.
AID135793Median Survival days of mice infected with L1210 leukemia cells at dose 1 mg/kg relative to that of 9 days for control1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Methotrexate analogues. 28. Synthesis and biological evaluation of new gamma-monoamides of aminopterin and methotrexate.
AID237448Ratio of Vmax, rel to Km (FPGS substrate activity) for recombinant human FPGS2005Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16
Synthesis of classical, four-carbon bridged 5-substituted furo[2,3-d]pyrimidine and 6-substituted pyrrolo[2,3-d]pyrimidine analogues as antifolates.
AID57140Inhibitory activity against Leu22-Phe mutant human Dihydrofolate reductase1995Journal of medicinal chemistry, Mar-03, Volume: 38, Issue:5
2,4-Diamino-5-substituted-quinazolines as inhibitors of a human dihydrofolate reductase with a site-directed mutation at position 22 and of the dihydrofolate reductases from Pneumocystis carinii and Toxoplasma gondii.
AID230505Ratio of relative Vmax to that of Km values.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Folic acid analogues lacking the 2-carbon are substrates for folylpolyglutamate synthetase and inhibit cell growth.
AID71517Activity of substrate for human FPGS was evaluated and compared to that of aminopterin (AMT)1998Journal of medicinal chemistry, Apr-23, Volume: 41, Issue:9
Synthesis and biological activities of tricyclic conformationally restricted tetrahydropyrido annulated furo[2,3-d]pyrimidines as inhibitors of dihydrofolate reductases.
AID91046Inhibition of growth (cytotoxicity) of HuTu 80 cell line in vitro1983Journal of medicinal chemistry, Aug, Volume: 26, Issue:8
Novel fluorinated antifolates. Enzyme inhibition and cytotoxicity studies on 2'- and 3'-fluoroaminopterin.
AID98420Minimum inhibitory concentration of compound was tested for growth inhibition of L1210 cells.1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Synthesis and antitumor activity of 10-alkyl-10-deazaminopterins. A convenient synthesis of 10-deazaminopterin.
AID120945In vivo antitumor activity was evaluated against L1210 leukemia implanted mice by measuring T/C median after intraperitoneal administration of compound at 0.12 mg/kg; T/C median=14/81984Journal of medicinal chemistry, May, Volume: 27, Issue:5
Methotrexate analogues. 19. Replacement of the glutamate side chain in classical antifolates by L-homocysteic acid and L-cysteic acid: effect on enzyme inhibition and antitumor activity.
AID30125Kinetic parameter Vmax of the compound2002Journal of medicinal chemistry, Nov-07, Volume: 45, Issue:23
Synthesis of classical and nonclassical, partially restricted, linear, tricyclic 5-deaza antifolates.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID1480224Toxicity in collagen-induced DBA/1J mouse arthritis model assessed as decrease in body weight at 6.8 mg/kg, ip administered daily for 2 weeks starting on day 27 post first immunization measured up to day 332018Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8
Synthesis and Evaluation of Hydrogen Peroxide Sensitive Prodrugs of Methotrexate and Aminopterin for the Treatment of Rheumatoid Arthritis.
AID22587Activity is determined as substrate for CCRF-CEM human leukemia cell folyl-poly-glutamate synthetase1994Journal of medicinal chemistry, Apr-15, Volume: 37, Issue:8
Classical and nonclassical furo[2,3-d]pyrimidines as novel antifolates: synthesis and biological activities.
AID89332Compound was tested for its inhibitory concentration against human leukemic lymphoblasts (CEM Cells)1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Methotrexate analogues. 28. Synthesis and biological evaluation of new gamma-monoamides of aminopterin and methotrexate.
AID135788Median Survival days of mice infected with L1210 leukemia cells at dose 0.5 mg/kg relative to that of 9 days for control1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Methotrexate analogues. 28. Synthesis and biological evaluation of new gamma-monoamides of aminopterin and methotrexate.
AID89333Compound was tested for its inhibitory concentration against human leukemic lymphoblasts (CEM Cells) and a resistant subline (CEM / MTX).1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Methotrexate analogues. 28. Synthesis and biological evaluation of new gamma-monoamides of aminopterin and methotrexate.
AID71205Activity (relative Vmax) was evaluated in vitro by purified mouse liver folate polyglutamate synthetase (FPGS). 1985Journal of medicinal chemistry, Jul, Volume: 28, Issue:7
Synthesis of the antileukemic agents 5,10-dideazaaminopterin and 5,10-dideaza-5,6,7,8-tetrahydroaminopterin.
AID100337Compound was tested for its inhibitory concentration to inhibit the growth of wild type L1210 cells and a subline (L1210 / R81).1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Methotrexate analogues. 28. Synthesis and biological evaluation of new gamma-monoamides of aminopterin and methotrexate.
AID71490Specific activity of L1210 Folyl-polyglutamate synthase1993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Studies on analogues of classical antifolates bearing the naphthoyl group in place of benzoyl in the side chain.
AID57298Inhibition of dihydrofolate reductase (DHFR) from mouse cells (L1210/R71).1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Synthesis and biological activity of methotrexate analogues with two acid groups and a hydrophobic aromatic ring in the side chain.
AID409956Inhibition of mouse brain MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID71360Substrate activity against CCRF-CEM human leukemia cell Folyl-polyglutamate synthase1995Journal of medicinal chemistry, Sep-15, Volume: 38, Issue:19
Effect of bridge region variation on antifolate and antitumor activity of classical 5-substituted 2,4-diaminofuro[2,3-d]pyrimidines.
AID71200Activity (apparent Km ) was evaluated in vitro by purified mouse liver folate polyglutamate synthetase (FPGS). 1985Journal of medicinal chemistry, Jul, Volume: 28, Issue:7
Synthesis of the antileukemic agents 5,10-dideazaaminopterin and 5,10-dideaza-5,6,7,8-tetrahydroaminopterin.
AID1653496Inhibition of Mycobacterium smegmatis ATCC 607 dihydrofolic reductase2019Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13
Insights of synthetic analogues of anti-leprosy agents.
AID71356Activity of compound calculated as Km was tested as substrate for human Folyl-polyglutamate synthase2003Journal of medicinal chemistry, Feb-13, Volume: 46, Issue:4
Design, synthesis, and biological activities of classical N-[4-[2-(2-amino-4-ethylpyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid and its 6-methyl derivative as potential dual inhibitors of thymidylate synthase and dihydrofolate reductase and
AID237692Vmax, rel (FPGS substrate activity) for recombinant human FPGS2005Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16
Synthesis of classical, four-carbon bridged 5-substituted furo[2,3-d]pyrimidine and 6-substituted pyrrolo[2,3-d]pyrimidine analogues as antifolates.
AID110836In vivo antitumor activity was evaluated against L1210 leukemia implanted mice by measuring percent increase in life span after intraperitoneal administration of compound at 0.12 mg/kg1984Journal of medicinal chemistry, May, Volume: 27, Issue:5
Methotrexate analogues. 19. Replacement of the glutamate side chain in classical antifolates by L-homocysteic acid and L-cysteic acid: effect on enzyme inhibition and antitumor activity.
AID98750In vitro inhibition of L1210 cell growth in rodent neoplastic cells1982Journal of medicinal chemistry, Jul, Volume: 25, Issue:7
10-Propargylaminopterin and alkyl homologues of methotrexate as inhibitors of folate metabolism.
AID218437Compound was evaluated for growth inhibition of WI-L2 cells. 1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Synthesis and biological activity of methotrexate analogues with two acid groups and a hydrophobic aromatic ring in the side chain.
AID71203Activity (relative Km ) was evaluated in vitro by purified mouse liver folate polyglutamate synthetase (FPGS). 1985Journal of medicinal chemistry, Jul, Volume: 28, Issue:7
Synthesis of the antileukemic agents 5,10-dideazaaminopterin and 5,10-dideaza-5,6,7,8-tetrahydroaminopterin.
AID23296Ratio between Vmax and Km for compound as substrate for recombinant human folyl-poly-glutamate synthase (FPGS)2000Journal of medicinal chemistry, Oct-19, Volume: 43, Issue:21
Design, synthesis, and X-ray crystal structure of a potent dual inhibitor of thymidylate synthase and dihydrofolate reductase as an antitumor agent.
AID66157In vitro membrane transport activity in Ehrlich cells in rodent1982Journal of medicinal chemistry, Jul, Volume: 25, Issue:7
10-Propargylaminopterin and alkyl homologues of methotrexate as inhibitors of folate metabolism.
AID44198Relative activity when compared to the activity of aminopterin in CCRF-CEM Human leukemia cell at a concentration of 50 uM1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Folate analogues. 34. Synthesis and antitumor activity of non-polyglutamylatable inhibitors of dihydrofolate reductase.
AID1653935Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs in presence of ROS scavenger pyruvate by Alamar blue assay2020Bioorganic & medicinal chemistry, 01-15, Volume: 28, Issue:2
Auxiliary in vitro and in vivo biological evaluation of hydrogen peroxide sensitive prodrugs of methotrexate and aminopterin for the treatment of rheumatoid arthritis.
AID18068Activity is determined as substrate for CCRF-CEM human leukemia cell folyl-poly-glutamate synthetase1994Journal of medicinal chemistry, Apr-15, Volume: 37, Issue:8
Classical and nonclassical furo[2,3-d]pyrimidines as novel antifolates: synthesis and biological activities.
AID57303Inhibitory activity against dihydrofolate reductase(DHFR) isolated from L1210 murine leukemia cells1988Journal of medicinal chemistry, Apr, Volume: 31, Issue:4
Methotrexate analogues. 31. Meta and ortho isomers of aminopterin, compounds with a double bond in the side chain, and a novel analogue modified at the alpha-carbon: chemical and in vitro biological studies.
AID22817The maximum velocity at which substrate concentration is stabilised is determined for compound as substrate for recombinant human folyl-poly-glutamate synthase (FPGS)2000Journal of medicinal chemistry, Oct-19, Volume: 43, Issue:21
Design, synthesis, and X-ray crystal structure of a potent dual inhibitor of thymidylate synthase and dihydrofolate reductase as an antitumor agent.
AID56984Tested for inhibitory concentration against human dihydrofolate reductase(DHFR)1994Journal of medicinal chemistry, Jul-08, Volume: 37, Issue:14
Synthesis and biological activity of N omega-hemiphthaloyl-alpha,omega- diaminoalkanoic acid analogues of aminopterin and 3',5-dichloroaminopterin.
AID230667Ratio of Vmax to Km1995Journal of medicinal chemistry, Sep-15, Volume: 38, Issue:19
Effect of bridge region variation on antifolate and antitumor activity of classical 5-substituted 2,4-diaminofuro[2,3-d]pyrimidines.
AID282579Ratio of Vmax to Km of human recombinant cytosolic FPGS2004Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27
Synthesis of classical, three-carbon-bridged 5-substituted furo[2,3-d]pyrimidine and 6-substituted pyrrolo[2,3-d]pyrimidine analogues as antifolates.
AID524794Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID99174Cell growth inhibition against mouse leukemia L1210/R71 cells1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
Methotrexate analogues. 25. Chemical and biological studies on the gamma-tert-butyl esters of methotrexate and aminopterin.
AID96459Compound was evaluated for the growth inhibition of L1210 cells.1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Synthesis and biological activity of methotrexate analogues with two acid groups and a hydrophobic aromatic ring in the side chain.
AID98499Tested for cell-growth inhibition against mouse leukemic L1210 cells1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
Methotrexate analogues. 34. Replacement of the glutamate moiety in methotrexate and aminopterin by long-chain 2-aminoalkanedioic acids.
AID69584Inhibition constant (Ki) was determined in Escherichia coli1983Journal of medicinal chemistry, Aug, Volume: 26, Issue:8
Novel fluorinated antifolates. Enzyme inhibition and cytotoxicity studies on 2'- and 3'-fluoroaminopterin.
AID98001Ability to inhibit L1210 murine leukemia tumor cell growth in culture after 48 hr of its exposure.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Analogues of methotrexate and aminopterin with gamma-methylene and gamma-cyano substitution of the glutamate side chain: synthesis and in vitro biological activity.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2013Proceedings of the National Academy of Sciences of the United States of America, Sep-17, Volume: 110, Issue:38
Structures of human folate receptors reveal biological trafficking states and diversity in folate and antifolate recognition.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,316)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990921 (69.98)18.7374
1990's181 (13.75)18.2507
2000's94 (7.14)29.6817
2010's95 (7.22)24.3611
2020's25 (1.90)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 44.71

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index44.71 (24.57)
Research Supply Index7.29 (2.92)
Research Growth Index4.33 (4.65)
Search Engine Demand Index73.40 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (44.71)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials73 (5.26%)5.53%
Reviews99 (7.13%)6.00%
Case Studies42 (3.02%)4.05%
Observational0 (0.00%)0.25%
Other1,175 (84.59%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (13)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase 1, Open-label, Dose-finding Study of Pralatrexate Plus Systemic Bexarotene in Patients With Relapsed or Refractory Cutaneous T Cell Lymphoma [NCT01134341]Phase 134 participants (Actual)Interventional2010-03-31Completed
A Randomized Phase 1 Study Comparing The Safety and Oral Pharmacokinetics Of 0.25 mg and 1.0 mg Aminopterin Tablets In Human Subjects With Psoriasis [NCT00937027]Phase 122 participants (Actual)Interventional2009-06-30Completed
A Phase 2 Double-Blind, Placebo-Controlled, Randomized Dose Finding Study For The Efficacy And Safety Of Aminopterin In Methotrexate-Naive Rheumatoid Arthritis [NCT01724931]Phase 2175 participants (Actual)Interventional2013-02-28Completed
A Multi-Center, Phase 2, Open-Label Study of (RS)-10-Propargyl-10-Deazaaminopterin (Pralatrexate) With Vitamin B12 and Folic Acid Supplementation in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma [NCT00364923]Phase 2115 participants (Actual)Interventional2006-08-31Completed
A Phase 1/2a Open-label Study of Pralatrexate and Gemcitabine With Vitamin B12 and Folic Acid Supplementation in Patients With Relapsed or Refractory Lymphoproliferative Malignancies [NCT00481871]Phase 1/Phase 2119 participants (Actual)Interventional2007-05-31Completed
CINJALL: Treatment for Children With Acute Lymphocytic Leukemia [NCT00176462]Phase 260 participants (Actual)Interventional2001-02-28Completed
A Phase 1, Open-label Study of Pralatrexate With Vitamin B12 and Folic Acid Supplementation in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma [NCT00554827]Phase 155 participants (Actual)Interventional2007-08-31Completed
A Multi-center, Randomized, Phase 3 Study of Sequential Pralatrexate Versus Observation in Patients Previously Undiagnosed Peripheral T-cell Lymphoma Who Achieved an Objective Response After Initial Treatment With CHOP-based Chemotherapy [NCT01420679]Phase 321 participants (Actual)Interventional2011-08-31Terminated
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial to Establish the Efficacy and Safety of Once-Weekly Oral Aminopterin for the Treatment of Subjects With Moderate-To-Severe Psoriasis [NCT03431974]Phase 219 participants (Actual)Interventional2018-11-01Completed
Phase 2 Study of Pralatrexate in Female Patients With Previously-treated Advanced or Metastatic Breast Cancer [NCT01118624]Phase 222 participants (Actual)Interventional2010-03-31Completed
A Phase II Trial of Aminopterin in Adults and Children With Refractory Acute Leukemia Grant Application Title: A Phase II Trial of Aminopterin in Acute Leukemia [NCT00003305]Phase 275 participants (Anticipated)Interventional1997-07-31Completed
Phase II Trial of Aminopterin in Patients With Persistent or Recurrent Endometrial Carcinoma [NCT00003821]Phase 20 participants (Actual)Interventional1998-01-31Withdrawn
A Phase 2, Single-Arm Study of Pralatrexate in Patients With Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder [NCT00722553]Phase 230 participants (Actual)Interventional2008-07-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00176462 (1) [back to overview]Percentage of Patients With ALL at High Risk of Relapse (Arm 2) Who Were Relapse-free at 5 Years
NCT00364923 (4) [back to overview]Duration of Response Per Independent Central Review
NCT00364923 (4) [back to overview]Overall Survival Per Independent Central Review
NCT00364923 (4) [back to overview]Progression-free Survival Per Independent Central Review
NCT00364923 (4) [back to overview]Response Rate Per Independent Central Review
NCT00481871 (3) [back to overview]Duration of Response
NCT00481871 (3) [back to overview]Objective Responses Assessed by International Workshop Criteria (IWC)
NCT00481871 (3) [back to overview]Progression-free Survival (PFS) Time
NCT00722553 (5) [back to overview]Clinical Benefit Rate (CBR)
NCT00722553 (5) [back to overview]Duration of Response (DOR)
NCT00722553 (5) [back to overview]Objective Response Rate (ORR)
NCT00722553 (5) [back to overview]Overall Survival (OS)
NCT00722553 (5) [back to overview]Progression Free Survival (PFS)
NCT01118624 (4) [back to overview]Duration of Response (DOR)
NCT01118624 (4) [back to overview]Incidence of Adverse Events (AEs) and Laboratory Abnormalities
NCT01118624 (4) [back to overview]Objective Response Rate (ORR)
NCT01118624 (4) [back to overview]Overall Survival (OS)
NCT01420679 (2) [back to overview]Overall Survival (OS)
NCT01420679 (2) [back to overview]Number of Participants With Worst Grade Adverse Events (AEs), Deaths, Serious Adverse Events (SAEs), and SAEs Leading to Discontinuation of Study Treatment, and Worst Grade Laboratory Abnormalities
NCT03431974 (2) [back to overview]Subjects With >=75% Reduction in Baseline Psoriasis Area and Severity Index (PASI) (Efficacy)
NCT03431974 (2) [back to overview]Success (Score of 0 or 1) in Static Physician Global Assessment (sPGA) (Efficacy)

Percentage of Patients With ALL at High Risk of Relapse (Arm 2) Who Were Relapse-free at 5 Years

This measure looks at the percentage of patients on Arm 2 who did not experience a relapse at 5 years, where relapse is defined as the presence of progressive disease after the achievement of a complete remission. (NCT00176462)
Timeframe: 5 years

Interventionpercentage of participants (Number)
Arm 2 High Risk64.9

[back to top]

Duration of Response Per Independent Central Review

Calculated only for those pts with an objective response. Pts receiving subsequent therapy (including transplant) before progressive disease (PD) was documented were censored at date of last response assessment obtained prior to subsequent therapy, with a note indicating censoring occurrence & reason. Pts who withdrew consent to participate in the study prior to PD were censored at the date of their last evaluable assessment of response. Pts who withdrew from treatment prior to PD or initiation of subsequent therapy without withdrawing consent were followed for disease status when possible. (NCT00364923)
Timeframe: Measured from the first day of documented response, assessed at prior to every other even-numbered cycle (every 14 weeks) until disease progression or death for up to 2 years after initial dose

InterventionDays (Median)
Evaluable Population306

[back to top]

Overall Survival Per Independent Central Review

Calculated as date of death - date of enrollment +1, estimated using the product-limit estimator. Pts who had not died (no record of death) or were lost to follow-up were censored at the date of last contact. Pts who withdrew consent to participate in the study including consent to be followed, were censored on the date of withdrawal. Pts who withdrew from treatment without withdrawing consent were followed for survival status whenever possible. (NCT00364923)
Timeframe: Assessed every 14 weeks while on treatment, and after disease progression no less frequently than every 6 months for up to 2 years after first dose.

InterventionMonths (Median)
Evaluable Population14.5

[back to top]

Progression-free Survival Per Independent Central Review

Patients (pts) with subsequent therapy prior to PD were censored at date of last response assessment prior to subsequent therapy. Pts who were alive without PD were censored at the date of last assessment of first dose. Pts who withdrew consent to participate in the study prior to PD were censored at the date of their last disease assessment or treatment day 1. Pts who withdrew consent from treatment prior to PD without withdrawing consent for follow-up were followed for disease status & survival. Pts who did not have response assessments after baseline were censored at treatment day 1. (NCT00364923)
Timeframe: Calculated as the number of days from treatment day 1 to the date of disease progression or death, regardless of cause for up to 2 years after initial dose

InterventionDays (Median)
Evaluable Population106

[back to top]

Response Rate Per Independent Central Review

Patient response to treatment was determined by independent central review using International Workshop Criteria (IWC). Results present the best overall response. The initial response assessment was scheduled at week 7 (prior to Cycle 2) and then prior to every even-numbered cycle (every 14 weeks) for up to two years after first dose. (NCT00364923)
Timeframe: Response was assessed at 7 weeks (prior to Cycle 2) and then prior to every other even-numbered cycle (every 14 weeks) until disease progression or death for up to 2 years after initial dose

Interventionof Patients who Responded (Number)
Evaluable Population32

[back to top]

Duration of Response

Duration of response was defined as the number of days between the date of first tumor response assessment of objective response to the time of the first tumor response assessment of progressive disease (PD) or death due to any cause (date of first PD assessment or death - date of first objective response assessment + 1) (NCT00481871)
Timeframe: Response assessments were performed no less than every 3 cycles in the Phase 1 part of the study and every 8 weeks (± 1 week) in the Phase 2a part of the study

Interventiondays (Median)
Phase 1174
Phase 2 - Group B210
Phase 2 - Group C170

[back to top]

Objective Responses Assessed by International Workshop Criteria (IWC)

Number of participants who achieved an objective response. Objective response was defined as a tumor response assessment of either complete response (CR) or partial response (PR) and was determined only for patients with measurable disease at baseline. A tumor response assessment reported by IWC without PET was used for any analyses in cases where an IWC+PET evaluation was not done. (NCT00481871)
Timeframe: Assessed every 8 weeks (+/- 1 week) for Phase II and no less than every 3 cycles for Phase I

Interventionparticipants (Number)
Phase 18
Phase 2 - Group B5
Phase 2 - Group C7

[back to top]

Progression-free Survival (PFS) Time

PFS time was calculated as the number of days from study day 1 to the date of PD or death, regardless of cause (date of PD or death - study day 1 + 1). (NCT00481871)
Timeframe: Response assessments were performed no less than every 3 cycles in the Phase 1 part of the study and every 8 weeks (± 1 week) in the Phase 2a part of the study

Interventiondays (Median)
Phase 153.0
Phase 2 - Group B59.0
Phase 2 - Group C54.0

[back to top]

Clinical Benefit Rate (CBR)

The number of patients with a best confirmed or unconfirmed response of CR, PR, or stable disease (SD) for at least 24 weeks (approximately 5.5 months) (NCT00722553)
Timeframe: Assessed at the end of each even-numbered cycle (every 8 weeks) or per standard of care, but no more than every 12 weeks (+/- 1 week) if treatment has ended, for up to 2 years after enrollment.

Interventionparticipants (Number)
Evaluable Population3

[back to top]

Duration of Response (DOR)

Duration of time from when tumor measurement criteria were met for CR or PR (whichever status was recorded first) until the first date that recurrent disease or progressive disease (PD) or death was objectively documented. Progression is defined, using RECIST, as an increase in the smallest dimension of any target or non-target lesion, or the appearance of new lesions, since baseline. Calculated for those patients with a best overall confirmed or unconfirmed response of CR or PR. (NCT00722553)
Timeframe: Measured from the first day of documented response for up to 2 years after enrollment.

InterventionDays (Median)
Evaluable Patients82

[back to top]

Objective Response Rate (ORR)

The number of patients with a best overall confirmed response of either complete response (CR) or partial response (PR) (NCT00722553)
Timeframe: Assessed at the end of each even-numbered cycle (every 8 weeks), or per standard of care but no more than every 12 weeks (+/- 1 week) if treatment has ended for up to 2 years after enrollment.

Interventionparticipants (Number)
Evaluable Population1

[back to top]

Overall Survival (OS)

The number of days from study day 1 to death. Patients who had not died (no record of death) or were lost to follow-up were censored at the date of last contact. (NCT00722553)
Timeframe: Assessed at the end of each even-numbered cycle (every 8 weeks), or per standard of care if treatment has ended (at least every 12 weeks) for up to 2 years after enrollment. After PD or start of subsequent treatment, OS will be assessed every 4 months.

InterventionMonths (Median)
Evaluable Population9.3

[back to top]

Progression Free Survival (PFS)

Length of time from study day 1 to the date of radiological evidence of PD (date of computed tomography [CT] or magnetic resonance imaging [MRI] scan, whichever indicates PD) or death, regardless of cause. (NCT00722553)
Timeframe: Assessed at the end of each even-numbered cycle (every 8 weeks), or per standard of care but no more than every 12 weeks (+/- 1 week) if treatment has ended, for up to 2 years after enrollment.

InterventionMonths (Median)
Evaluable Population4.0

[back to top]

Duration of Response (DOR)

One patient has a PR as response and duration of response was provided for that patient. (NCT01118624)
Timeframe: Assessed at the end of each even-numbered cycle (every 8 weeks), or per standard of care but no less than 4 weeks and nor more than every 12 weeks (+/- 1 week) if treatment has ended.

Interventiondays (Number)
Pralatrexate112

[back to top]

Incidence of Adverse Events (AEs) and Laboratory Abnormalities

(NCT01118624)
Timeframe: Recorded at all study visits: every 2 weeks while on treatment and at safety follow-up (35 +/- 5 days post-last dose) or early termination visit (at time of withdrawal).

Interventionparticipants (Number)
Pralatrexate21

[back to top]

Objective Response Rate (ORR)

Tumor response evaluation was performed using RECIST 1.0 using CT/MRI. Proportion of patients achieving a CR or PR is considered in the overall response. (NCT01118624)
Timeframe: Assessed at the end of each even-numbered cycle (every 8 weeks), or per standard of care but no less than 4 weeks and nor more than every 12 weeks (+/- 1 week) if treatment has ended.

Interventionparticipants (Number)
Pralatrexate1

[back to top]

Overall Survival (OS)

Number of days from first dose of pralatrexate to death. (NCT01118624)
Timeframe: Assessed at the end of each even-numbered cycle (every 8 weeks), or per standard of care but at least every 4 weeks and no more than every 12 weeks (+/- 1 week) if treatment has ended. OS will be collected for up to 2 years from start of pralatrexate.

Interventionmonths (Median)
Pralatrexate11.3

[back to top]

Overall Survival (OS)

Overall survival was defined as the time in days from randomization to the date of death, regardless of cause (date of death - date of randomization + 1). (NCT01420679)
Timeframe: From randomization until death (up to 76 months)

Interventionmonths (Median)
Pralatrexate ArmNA
Observation ArmNA

[back to top]

Number of Participants With Worst Grade Adverse Events (AEs), Deaths, Serious Adverse Events (SAEs), and SAEs Leading to Discontinuation of Study Treatment, and Worst Grade Laboratory Abnormalities

"An AE was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. An SAE was an AE resulting in any of following outcomes or deemed significant for any other reason: death, initial or prolonged inpatient hospitalization, life-threatening experience (immediate risk of dying), persistent or significant disability or incapacity, congenital anomaly. AE included both serious and non- SAEs. An AE of Hematology and Chemistry was collected and graded as per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 4.03, where Grade 3 refers to severe or medically significant but not immediately life threatening and Grade 4 refers to life-threatening consequences." (NCT01420679)
Timeframe: From first dose of study drug to 35 (±5) days after last dose of study drug for the Pralatrexate Arm, and until 35 (± 5) days after the study treatment discontinuation for the Observation Arm (Up to 2 years)

,
InterventionParticipants (Count of Participants)
Participants with Any Treatment Emergent AEsParticipants with Any Grade 3 - 4 AEsParticipants with Treatment Emergent AEs Resulting in DeathsParticipants with Treatment Emergent SAEsParticipants with Any SAEs Leading to Drug DiscontinuationHematology:Higher Than Grade 3/4 Lab AbnormalitiesChemistry:Higher Than Grade 3/4 Lab Abnormalities
Observation Arm6200010
Pralatrexate Arm14814231

[back to top]

Subjects With >=75% Reduction in Baseline Psoriasis Area and Severity Index (PASI) (Efficacy)

"As follows:~Area of Involvement. Determine a score, from 0 to 6, for each body section (head, trunk, upper limbs, lower limbs) based on the percent of psoriasis skin involvement: 0=0%, 1=<10%, 2=10% to <30%, 3=30% to <50%, 4=50% to <70%, 5=70% to <90%, 6=90% to 100%.~Severity of Involvement. Determine a score, from 0 to 4, for each body section (head, trunk, upper limbs, lower limbs), for the psoriatic skin severity of each of erythema, thickness, and scaling: 0=none, 1=slight, 2=moderate, 3=severe, 4=very severe. For each body section the three severity scores are summed.~For each body section the product of the Area and Severity is determined.~For each body section the product of line 3 is multiplied by an Area Factor (head=0.1, trunk=0.3, upper limbs=0.2, lower limbs=0.4).~A PASI score is determined by summing the 4 body section products (line 4). The highest possible score=72; the lowest possible score=0. The higher the scores, the worse the psoriasis." (NCT03431974)
Timeframe: 98 days.

InterventionParticipants (Count of Participants)
LD-Aminopterin Oral Capsule3
Placebo Oral Capsule1

[back to top]

Success (Score of 0 or 1) in Static Physician Global Assessment (sPGA) (Efficacy)

"As follows:~Induration. A score, from 0 to 5, based on: 0=No plaque elevation; 1= Minimal plaque elevation=0.25 mm; 2=Mild plaque elevation=0.5 mm; 3=Moderate plaque elevation=0.75 mm; 4=Marked plaque elevation=1.0 mm; 5=Severe plaque elevation>1.25 mm.~Erythema. A score, from 0 to 5, based on: 0=No erythema, hyperpigmentation may be present; 1=Faint erythema; 2=Light red coloration; 3=Moderate red coloration; 4=Bright red coloration; 5=Dusky to deep red coloration.~Scaling. A score, from 0 to 5, based on: 0= No scaling; 1=Minimal; occasional fine scale on<5% of the lesion; 2=Mild; fine scale predominates; 3=Moderate; coarse scale predominates; 4=Marked; thick, non-tenacious scale predominates; 5=Severe; very thick, tenacious scale predominates.~The sPGA: Induration, Erythema, and Scaling scores are rounded to the nearest whole number and averaged. 0=Cleared; 1=Minimal; 2=Mild; 3=Moderate; 4=Marked; 5=Severe. Higher score indicates worse psoriasis." (NCT03431974)
Timeframe: 98 days.

InterventionParticipants (Count of Participants)
LD-Aminopterin Oral Capsule1
Placebo Oral Capsule1

[back to top]